








































A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF BIOCHEMISTRY 
NATIONAL UNIVERSITY OF SINGAPORE 
2015 
	  	  









I sincerely dedicate this thesis to  
my dear Mum and Dad 
 






PHD is a journey full of learning and gaining the knowledge, also 
full of competitions and difficulties.  I appreciate the help from many 
people, without whom, I would not be able to finish this journey.  
First of all, I would like to express my sincere thanks to my 
supervisor A/P Ernesto Guccione, IMCB for giving me this great 
opportunity to pursue PHD in Singapore. He is such an extraordinary 
mentor, who always motivates and inspires people. He was always very 
patient and nice to discuss the project with me whenever I walked in his 
office.  
I would like to thank my co-supervisor A/P Robert Robinson, for 
allowing me to work in his lab and learning protein purification and X-ray 
crystallography over the past four years. He is the best mentor, who is 
always happy to discuss project with us and gives us a lot of freedom to 
work and study in the lab.   
I would like to thank the Agency for Science, Technology and 
Research (A*STAR), Singapore, for funding my PHD. 
I also want to express my thanks to Dr Jantana Wongsantichon for 
teaching me the basic skills about protein purification in my first year, and 
Dr Shimin Jiang for great help in solving crystal structure. To Saif, thank 
you for working one year with me, and doing a lot of cloning and protein 
purification experiments. To Tommaso, thank you for helping me work in 
cell culture. To Macro, for preparing the NPCs for heavy methyl SILAC. To 
	  	  
iv	  	  
Guene from Life Technologies, for her great help in discussing the data 
analysis of protein microarray.  
To Dr Carol, Joma and Jeffrey from ETC, for their important help in 
performing ITC and Mass spectrometry of PRDM9, and many discussions 
of this project. To Dr Michael and Tiziana and PhD student Valeria from 
European Institute of Oncology, Italy, for analyzing the heavy methyl 
SILAC dataset. To NTU Protein Production Platform, for the high-
throughput cloning and insect cell expression. To Dr Umesh, for his help in 
making phylogenetic tree of PMTs.  
To BR lab members: Albert, Khay Chun, Lin Jie, Lei Cheng, 
Habiba, Marten, Kriss, Pavithra, Diyva, Daavid, Bala, Wei Lin, Widya, 
Clement, Jennifer, Moses, Samson, Caner and David for their help in one 
way or another. To EG lab members: Macro, Slim, Jessica, Jabez, Ying 
Xim, Cheryl, Shivam, Diana, Jingxian, Florence, Chee Leng, Zhuang Li and 
Shun Xie for many discussions in every lab meeting. To Ekta, Semih and 
Gokhan from VT lab, for their kindness guidance on related experiments in 
cell biology.  
To my best friends: Xiaohong and Xinxing for making me 
motivated and companying me during the difficult times; and Lu Xiao for 
traveling overseas with me so many times and having a lot of grateful 
memories. 
My deepest gratitude to my dear family: my parents, for their 
unconditional love in every single day; my two brothers, for taking care of 





TABLE OF CONTENTS 
 
Chapter 1 Introduction ................................................................................ 1 
1.1 Epigenetic regulation ......................................................................... 1 
1.2 Protein arginine and lysine methylation ............................................ 1 
1.3 Protein arginine methyltransferases ................................................... 5 
1.4 Crystal structures of protein arginine methyltransferases .................. 6 
1.4.1 	   PRMT dimerization	  ..................................................................................	  6	  
1.4.2 	   Catalytic core domain of the PRMT family	  ...................................	  10	  
1.5 Transcriptional regulation of histone arginine methylation by 
PRMT1 and PRMT5 .................................................................................... 12 
1.5.1 	   PRMT1 in transcriptional regulation	  ................................................	  12	  
1.5.2 	   PRMT5 in transcriptional regulation	  ................................................	  12	  
1.6  Arginine methylation of non-histone proteins by PRMT1 and 
PRMT5 ......................................................................................................... 14 
1.6.1 	   PRMT1 and hnRNPs	  .............................................................................	  15	  
1.6.2 	   PRMT5 and mRNA splicing	  ...............................................................	  17	  
1.6.3 	   PRMT5 and cancer	  .................................................................................	  18	  
1.7  PRMT5 binding partners .................................................................. 21 
1.8  SET domain ..................................................................................... 21 
1.9 SET domain structure ...................................................................... 22 
1.10 PRDM family ................................................................................... 25 
1.10.1	   Functions of the PR domains in PRDM family	  ............................	  26	  
1.10.2	   Structures of PR and zinc finger domains	  ......................................	  27	  
1.11  Functions of histone lysine methylation .......................................... 29 
1.12 PRDM9 ............................................................................................ 29 
1.13 PRDM15 .......................................................................................... 30 
1.14 Rationale and significance of work .................................................. 31 
Chapter 2 Materials and methods ............................................................ 32 
2.1 Vectors and E. coli strains ............................................................... 32 
2.2 Antibodies ........................................................................................ 32 
2.3 Protein expression and purification ................................................. 33 
2.3.1	   Expression and purification of the PRMT5-MEP50 complex	  ......	  33	  
2.3.2	   Expression and purification of histone proteins	  ................................	  34	  
2.3.3	   Expression and purification of PRMT5 substrates and PRMT1	  ..	  34	  
	  	  
vi	  	  
2.3.4	   Expression and purification of PRDM9 and PRDM15	  ...................	  35	  
2.3.5	   Expression and purification of PRDM15 (29-174) for 
crystallization	  ...............................................................................................................	  36	  
2.4 Site directed mutagenesis ................................................................. 36 
2.5 In vitro radioactive methylation assay ............................................. 37 
2.6 Isolation and culture neural progenitor cells (NPCs) ....................... 37 
2.7 Heavy methyl SILAC for NPCs ...................................................... 38 
2.8 Immunoblotting ................................................................................ 39 
2.9 In vitro methylation on Protoarray® microarray ............................. 39 
2.10 Isothermal titration calorimetry (ITC) ............................................. 40 
2.11 Crystallization of mPRDM15 (29-174) ........................................... 40 
Chapter 3 Identifying novel substrates for protein arginine 
methyltransferase 5 .................................................................................... 41 
3.1 Dynamic changes of methylated arginine residues upon the deletion 
of PRMT5 .................................................................................................... 41 
3.2 Identification of novel substrates for PRMT5 using Protoarray® 
microarray approach .................................................................................... 48 
3.2.1	   Methodology of Protoarray® microarray system	  .............................	  48	  
3.2.2 	  	  	  	  Recombinant PRMT5-MEP50	  ................................................................	  49	  
3.2.3 	  	  	  	  PRMT5 substrate profiling with Protoarray® microarray	  .............	  50	  
3.2.4	   Targets identified only in the PRMT5 arrays	  .....................................	  52	  
3.2.5	   Targets identified in control and PRMT5 arrays	  ...............................	  55	  
3.3 In vitro validation of novel substrates for PRMT5 .......................... 59 
3.4 PRMT5 substrate specificity ............................................................ 62 
3.4.1	   PRMT5 targets Arg25 and Arg27 in CNBP	  .......................................	  62	  
3.4.2	   Glycine before target arginine site is important for PRMT5 
methylation	  ...................................................................................................................	  65	  
3.4.3	   Glycine after target arginine site is important for PRMT5 
methylation	  ...................................................................................................................	  67	  
3.5 Discussion ........................................................................................ 70 
3.5.1	   PRMT5 targets many RGG/RG motif-containing proteins	  ...........	  70	  
3.5.2	   Substrate specificity of PRMT5	  ..............................................................	  72	  
3.5.3	   Functional implications of arginine methylation by PRMT5	  .......	  73	  
3.5.4	   Comparison of two different approaches: hmSILAC and 
Protoarray® microarray	  ...........................................................................................	  74	  
3.5.5	   Demethylase	  ..................................................................................................	  75	  
Chapter 4 Biochemical studies of the PRDM9 and PRDM15 PR 
domains ....................................................................................................... 76 
	  	  
vii	  	  
4.1 The PRDM9 PR domain methylates histone H2A, H2B, H3 and H4 . 
  .......................................................................................................... 76 
4.2 Identification of methylated sites on histone H3 and H4 by PRDM9 . 
  .......................................................................................................... 78 
4.3 Binding affinity of PRDM9 to histone peptide H3 (1-21) and 
cofactor SAM ............................................................................................... 79 
4.4 Identification of non-histone substrates for PRDM9 by protein 
microarray .................................................................................................... 80 
4.5 Enzymatic activity of the PRDM15 PR domain on histones ........... 85 
4.6 Enzymatic activity of the PRDM15 PR domain on non-histone 
proteins ......................................................................................................... 87 
4.7 Crystallization and structural determination of the mouse PRDM15 
PR domain .................................................................................................... 88 
4.7.1	   Crystallization trials of the PRDM15 PR domain	  ............................	  88	  
4.7.2	   X-ray data collection of mPRDM15 (29-174) crystals	  ...................	  89	  
4.7.3	   Structure determination, model building and refinement	  ...............	  89	  
4.7.4	   Structure of PRDM15 PR domain	  .........................................................	  91	  
4.8 Discussion ........................................................................................ 96 
4.8.1	   PRDM9 activity towards histones	  ..........................................................	  96	  
4.8.2	   PRDM9 methylates non-histone substrates	  ........................................	  98	  
4.8.3	   PRDM15 PR domain is catalytic inactive	  ...........................................	  98	  
Chapter 5 Discussion and future research ............................................. 100 
5.1 Discussion ...................................................................................... 100 
5.1.1	   Dynamic changes of methylated arginines upon the deletion of 
PRMT5	  .......................................................................................................................	  100	  
5.1.2	   Potential functions of PRMT5 methylation on KHDRBS1	  ........	  102	  
5.1.3	   Potential functions of PRMT5 methylation on TRIP6	  .................	  104	  
5.1.4	   Biochemical studies of the PRDM9 and PRDM15 PR domains	  ......	  	   	  .........................................................................................................................	  104	  
5.1.5 	  	  	  Potential roles of PRDM9 methylation on EDC3	  ..........................	  106	  
5.1.6	   Protoarray® microarray	  ..........................................................................	  106	  
5.1.7 	  	  	  Arginine and lysine methylation	  ..........................................................	  108	  
5.2 Future work .................................................................................... 108 
5.2.1	   Functional effects of arginine methylation on SFPQ	  ...................	  108	  
5.2.2	   Functional effects of symmetric arginine dimethylation of 
KHDRBS1 by PRMT5	  ..........................................................................................	  109	  
5.2.3	   Functional effects of arginine methylation of hnRNPs by PRMT5	  .	  	   	  .........................................................................................................................	  109	  
5.2.4	   Functional studies of arginine methylation of TRIP6	  ..................	  110	  
	  	  
viii	  	  
5.2.5	   Substrate profiling of PRMT9 and PRMT1 using the Protoarray® 
microarray	  ..................................................................................................................	  111	  
5.2.6	   Determination of EDC3 methylation by PRDM9 in vivo	  ...........	  111	  
Bibliography ............................................................................................. 112 





Protein arginine and lysine methylation are the commonly utilized 
post-translational modifications in cells. Protein arginine methyltransferase 
5 (PRMT5) is a major type II methyltransferase that catalyzes the 
symmetric dimethylation of arginine residues on a wide variety of 
substrates and regulates multiple cellular processes, such as transcriptional 
regulation, splicing, and cell cycle progression. However, there is not a 
systematic characterization of PRMT5 targets.  In order to identify new 
high-confidence methylated sites for PRMT5, we first utilized heavy methyl 
SILAC in combination with high resolution LC-MS/MS analysis on wild 
type or PRMT5 knockout neural stem/progenitor cells (NPCs). We also 
profiled PRMT5 putative targets by performing methylation on a human 
protein microarray-based platform. Among these targets, cellular nucleic-
acid-binding protein (CNBP) was selected to further study the substrate 
specificity of PRMT5.  
  The PRDM (PRDI-BF1 and RIZ homology domain containing) 
family of putative lysine methyltransferases is characterized by an N-
terminal PR catalytic domain and a variable number of C-terminal zinc 
fingers. In this study, we focus on the biochemical characterization of 
PRDM9, which was described to only tri-methylate H3K4, and the 
uncharacterized PRDM15. In vitro methylation assays suggest the catalytic 
activity of PRDM9 PR domain is far more extensive than previously 
described. PRDM9 PR domain is able to methylate histone H2A, H2B, H3 
and H4 under saturating reaction condition. However, histone H3 is still the 
most prevalent substrate for PRDM9. With limited amount of PRDM9 and 
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SAM, only H3K4 was mono-, di-, and tri-methylated and H4K20 was 
mono-methylated. By performing the methylation assay on protein 
microarray, we found that PRDM9 can methylate additional non-histone 
substrates. On the contrary, PRDM15 PR domain is catalytically inactive on 
both histones and non-histone substrates. Indeed, we solved the crystal 
structure of PRDM15 PR domain, which suggests that this PR domain 
cannot accommodate the binding of SAM, a critical cofactor for 
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 INTRODUCTION 	  
 
1.1 EPIGENETIC REGULATION  
The term “epigenetics” refers to the alterations in gene expression 
without any change in DNA sequences (Egger et al. 2004). The epigenetic 
regulations include DNA methylation, histone modification and RNA-
associated silencing. In eukaryotes, nucleosome is the fundamental unit of 
chromatin that comprises four core histone proteins (H2A, H2B, H3, and H4) 
surrounded by approximately two turns of DNA (Finkenstadt & Millane, 
1998). DNA methylation occurs on cytosine and adenine nucleotides. DNA 
methylation on the 5-carbon on cytosine (5mC) has been considered as an 
epigenetic silencing mechanism. DNA methylation of CpG sites has various 
roles in transcriptional repression, transposon and viral DNA silencing (Egger 
et al. 2004). Histone proteins can be modified by covalently adding new 
functional groups, such as phosphate, acetyl, ubiquitin, or methyl groups on 
specific residues. Post-translational modifications (PTMs) of histones play 
critical roles in the important DNA regulatory processes including replication, 
repair and transcription.  
 
1.2  PROTEIN ARGININE AND LYSINE METHYLATION 
Of these epigenetic marks, methylation is one of the most abundant 
PTMs for histone proteins. Histone methylation can take place on positively 
charged arginine and lysine residues, as well as glutamine (Paik & Kim 1986; 
Polevoda & Sherman 2007; Tessarz et al. 2014). On non-histone proteins, 
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methylation has also been demonstrated to occur on additional amino acids 




Figure 1.1 Graphic illustration of protein arginine methylation by protein 
arginine methyltransferases (PRMTs). All type I, II and III PRMTs can 
catalyze the mono-arginine methylation by transferring the methyl group from 
S-adenosylmethionine (SAM) to the ω-guanidino group of arginine residues.  
In addition, type I PRMTs further add a second methyl group on the same 
terminal nitrogen atom and give rise to asymmetric dimethylarginine (ADMA).  
Type II PRMTs transfer a second methyl group to the other terminal nitrogen 
atom, resulting in the formation of symmetric dimethylarginine (SDMA). 
Type III PRMTs can only catalyze monomethylation (MMA). Type IV 
PRMTs monomethylates the internal (or δ) guanidino nitrogen atom.  
 
Protein arginine and lysine methylation are catalyzed by protein 
arginine methyltransferases (PRMTs) (Figure 1.1) and protein lysine 
methyltransferases (PKMTs), respectively (Figure 1.2). In protein arginine 
methylation, a methyl group is transferred from cofactor S-adenosyl-L-
	  	  
3	  	  
methionine (SAM) to the guanidino side chain of arginine residues, and SAM 
is further converted to S-adenosyl-L-homocysteinine (SAH). Arginine residues 
in proteins can be subject to mono-, asymmetric di- and symmetric di-
methylation by PRMTs (Figure 1.1). The PRMT family is characterized by a 
conserved 310 amino acids of PRMT core domain. Lysine methylation occurs 
on the ε-amino group of lysine residues with mono-, di-, or tri-methylation by 
PKMTs (Figure 1.2). The PKMT family harbors an approximately 130 amino 
acid of SET domain, which was named after the Drosophila proteins 
Suppressor of variegation 3–9 [Su(var)3–9] (Tschiersch et al. 1994), Enhancer 
of zeste [E(z)] (Jones & Gelbart 1993), and Trithorax (Trx) (Stassen et al. 
1995).  A phylogenetic tree of PRMTs and PKMTs illustrates the evolutionary 





Figure 1.2 Graphic illustration of protein lysine methylation by protein lysine 
methyltransferases (PKMTs). Specific lysine residues on a protein can be 







Figure 1.3 Phylogenetic tree of protein methyltransferases (PMTs). The 
phylogenetic tree was based on a multiple sequence alignment of the catalytic 
domain of protein arginine and lysine methyltransferases. Multiple sequence 
alignments (MSA) were constructed by MUSCLE (Edgar 2004). Prior to 
phylogenetic tree construction, columns in the MSA with a > 50% gap were 
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deleted. Maximum likelihood phylogenetic trees were calculated by the 
FastTree program (Price et al. 2010) utilizing a LG substitution matrix. The 
Shimodaira-Hasegawa test (Shimodaira & Hasegawa 1989) with 1000 
resamples of site likelihoods was performed to estimate the local branch 
support values in the tree. The phylogenetic tree was visualized by FigTree.  
 
 
1.3  PROTEIN ARGININE METHYLTRANSFERASES 
The PRMT family is conserved from yeast to human. Based on the 
addition of methyl marks on arginine residues, PRMTs are classified as type I, 
type II, type III and type IV (Figure 1.1). All types can catalyze the formation 
of ω-NG-monomethylarginine (ω-NG-MMA) on guanidino nitrogen atom of 
arginine residue. Type I enzymes (PRMT1, -2, -3, -4 (CARM1), -6, and -8) 
can additionally catalyze asymmetric ω-NG, NG-dimethylarginine (ω-NG, NG-
ADMA) by adding a second methyl group on the same nitrogen atom. Type II 
enzymes (PRMT5 and PRMT9) can catalyze the formation of symmetric ω-NG, 
N’G-dimethylarginine (ω-NG, N’G-SDMA) with a second methyl group added 
on the other terminal nitrogen atom. However, type III PRMT can only 
generate ω-NG-monomethylarginine (MMA) on substrates. Currently, PRMT7 
was identified as the only type III methyltransferase (Feng et al. 2013; Zurita-
Lopez et al. 2012). Other than the three types described above, type IV 
methyltransferases modulate the formation of δ-NG-methylarginine (δ-NG-






Figure 1.4 Schematics of the protein arginine methyltransferase (PRMT) 
family domain organization. All PRMTs contain at least one typical 
methyltransferase (MTase) domain (pink). Additional domains in PRMTs 
include: SH3 domain (red), zinc finger motif (blue), myristoylation motif 
(Myr) and tetratricopeptide domains (TPR) (green). This figure was drawn 
using DOG 1.0 (Ren et al. 2009). 
 
1.4 CRYSTAL STRUCTURES OF PROTEIN ARGININE 
METHYLTRANSFERASES  
 
1.4.1  PRMT dimerization  
Both type I and II PRMTs form dimers via a dimerization arm that is 
located in C-termini.  Based on the solved structures, type I PRMTs are 
conserved in forming a typical head-to-tail homodimer. Dimerization is 
essential for their methylation activity. Mutant PRMT1 without the 
dimerization arm (188-222) was shown to be a monomer, which abolished its 
enzymatic activity (Figure 1.5A) (Zhang & Cheng 2003). The dimerization 
may function in the production of dimethylated arginine during a two-step 
process: monomethylation and dimethylation.  
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C. elegans PRMT5 adopts the typical head-to-tail conformation as seen 
for type I PRMTs, in which the N-terminal TIM barrel domain of one 
monomer interacts with the C-terminal catalytic domain of the other monomer 
(Sun et al. 2011). Crystal structures of human and Xenopus PRMT5 were 
solved in complex with a WD40 protein called MEP50 or WDR77 as a hetero-
octamer (Antonysamy et al. 2012; Ho et al. 2013). The PRMT5 protein 
consists of a TIM barrel domain and a catalytic domain. The PRMT5-MEP50 
complex is formed by a PRMT5 tetramer at the center of the complex and four 
MEP50 molecules interacting with the TIM barrel domains (Figure 1.5B). 
MEP50 can bind to the substrate and present it to PRMT5 (Ho et al. 2013). 
The PRMT5 dimerization domain (residues 488-494) is unique relative to the 
other PRMTs (Figure 1.5B). Two residues in this region, Arg488 and Asp491, 
form two salt bridges with Asp491 and Arg488 of adjacent monomer 
(Antonysamy et al. 2012). However, this domain in C. elegant PRMT5 differs 
in length and conformation.  So far, the importance of tetramerization is 
unclear for the function of the PRMT5 in the hetero-octameric complex. One 
hypothesis is that it may lead to the processive methylation of substrates. 
Alternatively it may function as landing pad for other binding partners (Ho et 
al. 2013). 
In the PRMT family, only PRMT7 and PRMT9 harbor two tandem 
PRMT core domains (Figure 1.4). Recent studies of the PRMT7 structure 
revealed that PRMT7 exists as a monomer in solution, but mimics the PRMT 
dimeric state with its two tandem core modules (Hasegawa et al. 2014; Cura et 
al. 2014) (Figure 1.5C). In these two core domains, only one domain was 
bound by cofactor SAM, the other was found to be in an inactive state because 
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of the lack of important sequence motif or residues for catalytic activity.  Most 
recently, the type II enzyme PRMT9 was found to methylate splicing factor 
145 (Yang et al. 2015). However, it is still unclear about the oligomerization 
state of PRMT9 in solution, the mechanism of symmetric dimethylarginine 
mediated by two core domains, and whether both core domains contain the 






Figure 1.5 Crystal structures of rat PRMT1, human PRMT5 and mouse 
PRMT7.  (A) Structure of rat PRMT1 in complex with SAH and R3 peptide 
(PDB: 1OR8; (Zhang & Cheng 2003) ). (B) Structure of human PRMT5-
MEP50 in complex with SAM analog (A9145C) and H4 peptide  (PDB: 
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4GQB; (Antonysamy et al. 2012)). (C) Structure of mouse PRMT7 in complex 
with SAH (PDB: 4C4A; (Cura et al. 2014)). The SAM binding domain is 
colored red, the β-barrel domain is yellow, the TIM domain is light pink, the 
dimerization arm is blue, the substrate is magenta and MEP50 is cyan. 
Cofactor SAH and SAM analog (A9145C) are shown as green sticks.   
 
1.4.2  Catalytic core domain of the PRMT family 
Crystal structures of PRMT1, PRMT3, PRMT4, PRMT5, PRMT6 and 
PRMT7 have been solved. These structures provide structural insights to 
understand the mechanism of substrate recognition and the methylation 
reaction of PRMT family.  PRMTs adopt a structurally conserved catalytic 
core module with approximately 310 amino acids. This catalytic core module 
normally consists of a SAM binding domain, a β-barrel domain and a 
dimerization arm (Figure 1.5) (Cura et al. 2014). Apart from the core module, 
PRMT proteins harbor other additional motifs in their N- or C-terminal 
regions, including SH3 and Zn finger domains (Figure 1.4). Type I PRMTs are 
characterized by the conserved YFXXY motif, the THW (threonine-histidine-
tryptophan) motif and a double-E loop, which are important for cofactor and 
substrate binding. Type II PRMT5 contains SYLQY instead of YFXXY and 
FSW instead of THW. The double-E loop is conserved in PRMT5, which 
forms salt bridges with the guanidine side-chain of substrate arginine.   
A phenylalanine residue in the active site of PRMT5 plays an 
important role in specifying the addition of second methyl group to the 
substrate.  Mutation of Phe379 to methionine in C. elegans PRMT5 (Phe327 
in human PRMT5) results in a mixture of SDMA and ADMA (Figure 1.6A) 
(Sun et al. 2011). In contrast to PRMT5, type I PRMT1 uses two conserved 
methionines (positions 48 and 155 in rat PRMT1) to sandwich the substrate 
arginine residue in the active site (Figure 1.6B) (Gui et al. 2011). By mutating 
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Met48 to phenylalanine, substrate formation of rat PRMT1 can be changed to 
a mixture of ADMA and a more minor amount of SDMA (Gui et al. 2014). 
Gas-phase calculations of the activation energy for methylarginine formation 
suggests that SDMA formation requires higher energy in comparison with 
ADMA (Gui et al. 2014). This might explain the limited amount of SDMA 
substrate.  This methionine is also conserved in type III PRMT7 (Figure 1.6C). 
However, the second methionine in PRMT7 is replaced by alanine, which 
seems to leave more space for the substrate arginine guanidinium moiety 
(Cura et al. 2014).  Thus, it is unknown why PRMT7 only catalyzes 
monomethylation from structure analysis.  
 
 
Figure 1.6 SAM binding pocket in PRMT5, PRMT1 and PRMT7. (A) 
Structure of rat PRMT1 in complex with SAH and R3 peptide (PDB: 1OR8; 
(Zhang & Cheng 2003) ). (B) Structure of human PRMT5-MEP50 in complex 
with SAM analog (A9145C) and H4 peptide  (PDB: 4GQB; (Antonysamy et al. 
2012)). (C) Structure of mouse PRMT7 in complex with SAH (PDB: 4C4A; 
(Cura et al. 2014)). Cofactor SAH and SAM analog (A9145C) are shown as 
green sticks.  The F327 in PRMT5, M48 and M155 in PRMT1, and M38 and 
A155 in PRMT7 are drawn as red sticks. The substrate arginine residues in 





1.5 TRANSCRIPTIONAL REGULATION OF HISTONE 
ARGININE METHYLATION BY PRMT1 AND PRMT5 
PRMT proteins are involved in various cellular process, including 
transcriptional regulation, RNA splicing, tumorigenesis and development. In 
the PRMT family, PRMT1 and PRMT5 are the predominant type I and type II 
arginine methyltransferase, respectively. They are able to directly methylate 
histones and many non-histone substrates in order to govern the wide-ranging 
biological roles.  
 
1.5.1  PRMT1 in transcriptional regulation 
PRMT1 catalyzes the asymmetric dimethylation of arginine 3 of 
histone H4 (H4R3me2a), which is a mark for transcriptional activation (Wang 
et al. 2001; Strahl et al. 2001). H4R3me2a facilitates the acetylation of lysines 
8 and 12 of H4 by p300 in vitro, while the acetylation of H4 inhibits Arg3 
methylation (Wang et al. 2001). A subsequent report showed that loss of 
H4R3 methylation by depleting PRMT1 led to a deficiency of histone 
acetylation on both H3 and H4 in vivo (Huang et al. 2005).  Moreover, it also 
resulted in an increase of H3K9me2 and H3K27me3 that are associated with 
inactive chromatin (Huang et al. 2005). Overall, PRMT1 mediates the 
transcriptional activation by dimethylating H4R3 to regulate the histone 
acetylation.   
 
1.5.2  PRMT5 in transcriptional regulation 
PRMT5, also called Janus kinase-binding protein 1 (JBP1), was 
originally identified as binding protein for Jak2 in yeast two-hybrid system 
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(Pollack et al. 1999). PRMT5 harbors the enzymatic activity towards histones 
H2AR3, H3R2, H3R8 and H4R3 and plays important roles in transcriptional 
regulation (Branscombe et al. 2001; Pal et al. 2004; Migliori et al. 2012). 
Symmetric dimethylation of H2AR3, H3R8 and H4R3 has been linked to 
repression of gene expression. During murine early development, PRMT5 
localizes to both the cytoplasm and the nucleus in a dynamic fashion. PRMT5 
is maternally inherited in the oocyte cytoplasm and translocates into the 
nucleus during the eight-cells to 16-cell stage transition (Tee et al. 2010). In 
ES cells, symmetric dimethylation of cytosolic H2A (H2AR3me2) by PRMT5 
leads to the repression of several differentiation genes (Tee et al. 2010). 
PRMT5 methylates H3R2, which recruits the binding of WDR5 and the MLL 
complex on euchromatin for transcriptional activation (Migliori et al. 2012). 
Histone H2A and H4 share the same five residues (NH2-SGRGK…) in their 
N-terminal tails. Symmetric dimethylation of H4R3 by PRMT5 recruits the 
DNA methyltransferase DNMT3A directly through the ADD domain (Zhao et 
al. 2009). Overexpression of PRMT5 leads to transcriptional silencing of 
genes coding γ-globin, while loss of PRMT5 results in loss of DNA 
methylation and gene activation (Zhao et al. 2009). In contrast to H4R3me2a 
that is linked to gene activation, symmetric dimethylation of H4R3 is 















Table 1.1 Summary of histone substrates for the PRMT family 
 
Name Enzyme classification Histone substrate 
PRMT1 Type I H4R3 (Strahl et al. 2001; Wang et al. 2001) 
PRMT2 Type I H4R3 (Lakowski & Frankel 2009) 
PRMT3 Type I N/A 
PRMT4/CARM1 Type I 
H3R2 (Schurter et al. 2001) 
H3R17 (Schurter et al. 2001) 
H3R26 (Schurter et al. 2001) 
PRMT5 Type II 
H2AR3 (Tee et al. 2010) 
H3R2 (Migliori et al. 2012) 
H3R8 (Pal et al. 2004) 
H4R3 (Pal et al. 2004) 
PRMT6 Type I H2AR29 (Waldmann et al. 2011) H3R2(Guccione et al. 2007) 
PRMT7 Type III 
H2AR3 (Karkhanis et al. 2012) 
H2BR29, H2BR31, H2BR33 (Feng et al. 
2013) 
H3R2 (Migliori et al. 2012) 
H4R3 (Karkhanis et al. 2012) 
PRMT8 Type I H2A (Sayegh et al. 2007) H4 (Sayegh et al. 2007) 
PRMT9/FXO11 Type II N/A 
 
 
1.6  ARGININE METHYLATION OF NON-HISTONE PROTEINS 
BY PRMT1 AND PRMT5 
The number of non-histone proteins identified as substrates for PRMT 
enzymes is growing. There is mounting evidence to suggest that RNA binding 
proteins (RBPs) are major targets for PRMT enzymes. So far, many RBPs 
have already been identified as substrates for PRMT1 (Table 1.2) and PRMT5 
(Table 1.3). Some of them can be methylated by both PRMT1 and PRMT5 at 






1.6.1  PRMT1 and hnRNPs 
PRMT1 is known to methylate many cellular proteins containing 
arginine and glycine rich motifs (RGG/RG) (Table 1.2) (J Tang et al. 2000; 
Klein et al. 2000). In addition, PRMT1 is also capable to recognize and 
methylate arginine residues beyond RGG paradigm including “RLG’’, 
‘‘RYG’’, ‘‘RFG’’, ‘‘RTG’’, and ‘‘RKG’’ (Smith et al. 1999; Wooderchak et 
al. 2008). Heterogeneous nuclear ribonucleoproteins (hnRNPs) are involved in 
pre-mRNA processing. Many of the hnRNPs have been found to contain 
methylated arginines in vivo (Liu & Dreyfuss 1995) and these methylated 
arginine sites were confirmed by heavy methyl SILAC MS (Ong et al. 2004). 
PRMT1 has been shown to directly methylate hnRNPA1, A2, K, U, UL1, and 
Q (Table 1.2). DNA/RNA binding protein hnRNPK contains several PTMs 
including phosphorylation, ubiquitination, sumoylation and arginine 
methylation. PRMT1 prefers to methylate Arg296 and Arg299 in hnRNPK, 
which inhibits the Ser302 phosphorylation by the pro-apoptotic kinase PKC. 
Loss of Ser302 phosphorylation results in an anti-apoptotic effect after DNA 
damage (Yang et al. 2014). Very recently, PRMT1 has been shown to 
methylate hnRNPUL1 in a RGG/RG motif (Gurunathan et al. 2015). Arginine 
methylation of hnRNPUL1 is important for the interaction with the DNA 
















Biological functions of 
arginine methylation Reference 
53BP1 Unknown function (Boisvert et al. 2005; Adams et al. 2005) 
Ash2L Unknown function (Butler et al. 2011) 
BCR Regulate calcium and PI-3 kinase pathways (Infantino et al. 2010) 
BRCA Influence transcriptional function (Guendel et al. 2010) 
CF Im59 and 
CF Im68 Unknown function (Martin et al. 2010) 
Chtop 
(C1orf77) 
Regulate Chtop and Nxf1 
interaction 
(Chang et al. 2013; van Dijk et al. 
2010) 
CIRP Regulate nucleus-cytoplasmic shuttling (Aoki et al. 2002) 
CNBP Impede RNA binding (Wei et al. 2014) 
E2F-1 Augment apoptosis (Zheng et al. 2013) 
ERα Regulate estrogen rapid signaling (Le Romancer et al. 2008) 
EWS Regulate subcellular localization (Araya et al. 2005) 
FGF-2 Unknown function (Klein et al. 2000) 
Fibrillarin Unknown function (Lin et al. 2002) 
FMRP Regulate protein-protein and protein-RNA interaction (Dolzhanskaya et al. 2006) 
hnRNPA1 Reduce single–stranded nucleic acids binding 
(Rajpurohit et al. 1994; Liu & 
Dreyfuss 1995) 
hnRNPA2 Unknown function (Friend et al. 2013) 
hnRNPK Anti-apoptosis (Yang et al. 2014) 
hnRNPQ Regulate nucleus-cytoplasmic shuttling (Passos et al. 2006) 
hnRNPR Unknown function (Wada et al. 2002) 
hnRNPU 
(SFA-A) Unknown function (Herrmann et al. 2004) 
hnRNPUL1 
Regulate interaction with 
NBS1 and recruitment to 
DNA damage sites 
(Gurunathan et al. 2015) 
ICP27 Unknown function (Souki et al. 2011) 
ILF3 Regulate DNA binding (Jie Tang et al. 2000; Cazanove et al. 2008) 
MRE11 Regulate DNA damage checkpoint control (Boisvert & Déry 2005) 





Biological functions of 
arginine methylation Reference 
p137GP1 Unknown function (Wada et al. 2002) 
PABPN1 Weaken the interaction with transportin 
(Smith et al. 1999; Fronz et al. 
2008; Fronz et al. 2011)  
RBP58 Unknown function (Wada et al. 2002) 
RHA Regulate subcellular localization (Smith et al. 2004) 
RUNX1 
Abrogate SIN3A binding and 
potentiate transcriptional 
activity 
(Zhao et al. 2008) 
Sam68 
(KHDRBS1) Nuclear localization (Papers et al. 2000; Bedford 2003) 
SAMT1 Unknown function (Wada et al. 2002) 
SFPQ Increase the mRNA binding of SFPQ (Snijders et al. 2015) 
SPT5 
Regulate interaction of SPT5 
with RNA polymerase II and 
transcriptional elongation 
(Kwak et al. 2003) 
STAT1 Modulate IFNα/β-induced transcription (Mowen et al. 2001) 
TAF15 Subcellular localization of TAF15 and gene regulation (Jobert et al. 2009) 
TLS/FUS 
Regulate nucleus-
cytoplasmic shuttling and 
stress granules formation 
(Yamaguchi & Kitajo 2012; Du et 
al. 2011) 
ZF5 Unknown function (Wada et al. 2002) 
 
 
1.6.2  PRMT5 and mRNA splicing 
The type II enzyme PRMT5 is also known to methylate RG stretches 
in vivo. Sm proteins (B/B’, D1, D2, D3, E, F and G) are essential components 
of U1, U2, U4 and U5 small nuclear ribonucleoproteins (snRNPs) in RNA 
processing. The Sm proteins B/B’, D1 and D3, containing RG rich elements at 
their C-termini, can be symmetrically dimethylated by PRMT5 (Friesen et al. 
2001). The SMN protein binds directly to these symmetric dimethyl-arginine 
tails via its tudor domain. The SMN complex is responsible for the loading of 
Sm proteins to snRNA (Pellizzoni et al. 2002). Loss of PRMT5 in mouse 
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neural stem/progenitor cells (NPCs) leads to the reduced methylation of Sm 
proteins, which results in the defects of core splicing machinery (Bezzi et al. 
2013).  
 
1.6.3  PRMT5 and cancer  
In many cases, knockdown of PRMT5 is correlated with reduced 
cellular proliferation while overexpression leads to cellular hyperproliferation 
(Wang et al. 2008; Pal et al. 2007). Elevated expression levels of PRMT5 are 
associated with different cancer types, including gastric, colorectal and lung 
cancer, and lymphoma and leukaemia (Pal et al. 2007; Wang et al. 2008; Wei 
et al. 2012; Kim et al. 2005). PRMT5 primarily localizes in the cytoplasm in a 
variety of somatic cells (Rho et al. 2001; Pal et al. 2007; Hou et al. 2008). In 
transformed lymphoid cell lines, PRMT5 was found to localize in both the 
nucleus and the cytoplasm, and protein levels were significantly up-regulated 
(Wang et al. 2008).  
PRMT5 is involved in the process of epithelial-mesenchymal transition 
(EMT). EMT plays important roles in cancer progression and results in higher 
efficiency of cancer migration and invasion. PRMT5 can be recruited to 
SNAIL via an interaction with AJUBA.  This multiprotein complex binds to 
the promoter region of E-cadherin, repressing the gene expression of E-
cadherin (Hou et al. 2008). Loss of E-cadherin is considered as a hallmark of 
EMT.  
PRMT5 also regulates p53. Tumor suppressor p53 plays important 
roles in cell proliferation, cell cycle progression and cell death (Scoumanne et 
al. 2009). In response to DNA damage, p53 undergoes arginine methylation at 
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R333, R335 and R337 by PRMT5. Arginine methylation on p53 influences the 
target gene specificity of p53 and inhibits its oligomerization (Jansson et al. 
2008). PRMT5-mediated methylation of p53 induces cell cycle arrest but not 
apoptosis. Overexpression of eIF4E is associated with elevation of 
proliferation and suppression of apoptosis. Arginine methylation of eIF4E by 
PRMT5 results in the suppression of cell growth and induces apoptosis (Zheng 
et al. 2013).  
JAK2-V617F is a constitutively activated form of JAK2, which is 
found in most patients with myeloproliferative neoplasms. Mutant JAK2 binds 
more strongly to PRMT5 in comparison with wild type, which leads to the 
phosphorylation of PRMT5. Phosphorylation of PRMT5 inhibits the 
interaction between PRMT5 and MEP50, and further causes the diminishment 
of PRMT5 methyltransferase activity (Liu et al. 2011). In summary, 
accumulating data suggest that PRMT5 plays important roles in 
















Biological functions of 
arginine methylation Reference 
Ash2L Unknown function (Butler et al. 2011) 
CA150 Unknown function (Cheng et al. 2007) 
CBP-1 Unknown function (Yang et al. 2009) 
CF Im68 Unknown function (Martin et al. 2010) 
Coilin Regulate the localization of SMN in Cajal bodies (Boisvert et al. 2002) 
E2F-1 Favor cell proliferation (Zheng et al. 2013) 
EBNA-2 Stimulate EBNA2-mediated transcription 
(Shire et al. 2006; Liu et al. 
2013) 
EGFR Inhibit ERK signaling and cell proliferation (Hsu et al. 2011) 
FEN1 Facilitate FCNA binding and DNA replication and repair (Guo et al. 2010) 
FGF-2 Regulate subcellular localization (Bruns et al. 2009) 
GM130 Maintain Golgi apparatus architecture (Zhou et al. 2010) 
HOXA9 
Endothelia cell expression of 
leukocyte adhesion 
molecules 
(Bandyopadhyay et al. 2012) 
KAP1 Affect the interaction between KAP1 and ZNF224 
(di Caprio et al. 2015) 
 
LSM4 Facilitate LSM4 binding to SMN (Brahms et al. 2001) 
MBP Maintain the integrity of myelin (Baldwin & Carnegie 1971) 
Nucleolin Unknown function (Teng et al. 2007) 
P53 Transcription regulation and self-oligomerization (Jansson et al. 2008) 
p65 Activate NFkB (Wei et al. 2013) 
PDCD4 Promote tumor cell viability (Powers et al. 2011)  (Fay et al. 2014) 
RSP10 Facilitate ribosome assembly and protein synthesis 





Regulate snRNP assembly (Brahms et al. 2000; Brahms et al. 2001) 
SPT5 
Regulate interaction of SPT5 
with RNA polymerase II and 
transcriptional elongation 





1.7  PRMT5 BINDING PARTNERS 
The catalytic activity of PRMT5 can be modulated by different binding 
partners. Among these binding partners, MEP50 directly binds to PRMT5 as 
heteroctamer and greatly stimulates the enzymatic activity of PRMT5 
(Antonysamy et al. 2012; Ho et al. 2013). MEP50 presents the protein 
substrates to PRMT5 methylation (Ho et al. 2013). However, excess MEP50 
inhibits PRMT5 enzymatic activity (Ho et al. 2013). The adaptor proteins 
pICln and RioK1 bind to N-terminus of PRMT5 in a mutually exclusive 
manner (Guderian et al. 2011). They serve in substrate presentation to specify 
different targets for PRMT5. pICln presents Sm protein for PRMT5 
methylation, however, RioK1 recruits the RNA-binding protein nucleolin by 
direct interaction (Guderian et al. 2011). CoPR5 directly binds to PRMT5 to 
form a subset of PRMT5-containing complex (Lacroix et al. 2008). The 
CoPR5-PRMT5 complex favors PRMT5 in targeting chromatin (Lacroix et al. 
2008). These PRMT5 interacting proteins localize either in the cytoplasm or in 
the nucleus to assist PRMT5 to execute diverse functions.  
 
1.8  SET DOMAIN 
With the exception of Dot1p, protein lysine methyltransferases 
(PKMTs) contain an evolutionarily conserved SET domain. To date, the SET 
domain has been found in a large number of eukaryotic proteins and also in 
some bacteria proteins (Kouzarides & Kouzarides 2002). Based on the 
sequence homology within the SET domain, SET domain-containing proteins 
are divided into four major subfamilies: SUV39, SET1, SET2, and RIZ 
(Kouzarides & Kouzarides 2002). SET domains are often associated with 
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multiple motifs including zinc fingers, Chromo domains, A/T hooks, PHD 
fingers, GTP-binding motifs. Some SET-containing proteins target both 
histone and non-histone substrates, while some only methylate non-histone 
substrates. There are still many uncharacterized SET domain-containing 
proteins to be studied. 
 
1.9 SET DOMAIN STRUCTURE 
SET domain is defined by several small β-sheets that surround a 
pseudo-knot structure, together with two conserved motifs, ELxF/YDY and 
NHS/CxxPN (Qian & Zhou 2006). Substrate and cofactor bind at opposite 
sides of the SET domain. A hydrophobic channel passes through the protein 
and links the substrate and cofactor. The sulfur atom of cofactor SAH points at 
the tip of target lysine side chain. The cofactor SAH forms hydrogen bonds 
with main-chain atoms of residues from the NHS/CxxPN motif and the GxG 
motif.  
The core SET domain is flanked by pre-SET, post-SET or I-SET 
motifs. None of these flanking amino acid sequences are conserved in all SET 
domain lysine methyltransferases. Human SET7/9, a H3K4 lysine 
methyltransferase, does not group in any of major SET domain subfamilies.  
The pre-SET domain of SET7/9 forms 12 antiparallel β-strands (Figure 1.7A). 
GLP is a H3K9 lysine methyltransferase from the SUV39 subfamily. The pre-
SET domain of GLP coordinates three zinc ions by nine cysteine residues to 







Figure 1.7 Structures of SET7/9, GLP, and the PR domains of PRDM2 and 
PRDM9. (A) Structure of human SET7/9 in complex with SAH and H3 
peptide (PDB: 1O9S; (Xiao et al. 2003)). (B) Structure of human GLP in 
complex with SAH and H3K9me peptide (PDB: 3HNA; (Wu, Min, V. V. 
Lunin, et al. 2010)). (C) Structure of human PRDM2 alone (PDB: 2JV0; 
(Briknarová et al. 2008)). (D) Structure of mouse PRDM9 in complex with 
SAH and H3K4me2 peptide (PDB: 4C1Q; (Wu et al. 2013)). The pre-SET 
domain is shown in cyan, the N-SET in orange, the SET in red and the post-
SET in yellow, and the substrate peptide in magenta. Zinc ions are shown as 
gray spheres and the cofactor SAH as green sticks.  
 
Structures of the post-SET domains adopt variable topologies. The 
post-SET region of SUV, SET1 and SET2 subfamilies contain three invariant 
cysteines (Zhang et al. 2002). These three cysteines may couple with the 
fourth cysteine (C244) from N241HxCxPN247 in DIM-5 to form additional zinc 
binding site (Zhang et al. 2002). Mutation of these three cysteines to serines in 
DIM-5 abolished its enzymatic activity (Zhang et al. 2002). GLP also contains 
this zinc finger motif in the post-SET region (Figure 1.7B). However, this 
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cysteine-rich region does not exist in SET7/9, SET8 and Rubisco 
methyltransferase. These data suggest that the post-SET domain is involved in 





Figure 1.8 Schematics of human PRDM family domain organization. PR 
domains are shown in red, zinc fingers in cyan, zinc knuckles in blue, and 






1.10 PRDM FAMILY  
The PRDM (PRDI-BF1 and RIZ homology domain containing) family 
is characterized by a conserved N-terminal PR domain, which was originally 
named from the PRDI-BF1 (PRDM1) and RIZ (PRDM2) homologous domain 
(Buyse et al. 1995) (Figure 1.3, Figure 1.8-1.9). The PR domain is a derivative 
of the SET domain and is only 20-30% identical to the SET domain in amino 
acid sequence. Thus it has diverged from the canonical SET domain structure 
(Sun et al. 2008; Wu, Min, V. V Lunin, et al. 2010). PR domains in all PRDM 
proteins contain a variable number of C2H2 Zn-finger repeats in their C-
terminal regions to confer DNA binding, with the exception of PRDM11. 
Prdm genes do not exist in fungi and plants. They first appeared in metazoans, 







Figure 1.9 Sequence alignment of PR domains of the PRDM family. Multiple 
sequence alignment was performed in ClustalW using the NPS® server. 
Secondary sequence assignment was run on ESPript 3.0 sever (Robert & 
Gouet 2014). Helices are indicated with squiggles, β-strands with arrows and 
turns by TT.  
 
 
1.10.1 Functions of the PR domains in PRDM family  
Although all PRDM family members contain a PR domain, the 
enzymatic activity of most of this family remains unclear. Only PRDM2, 
PRDM8, PRDM9, PRDM3 and PRDM16 have been shown to possess an 
intrinsic methyltransferase activity (Hayashi et al. 2005; Pinheiro et al. 2012; 
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Kim et al. 2003; Ross et al. 2012). PRDM2, PRDM3, PRDM8 and PRDM16 
have been found to methylate histone H3K9, and PRDM9 was identified as a 
H3K4 methyltransferase. Some other PRDM proteins have been shown to 
recruit other histone-modifying enzymes to execute their functions. For 
instance, PRDM1 is catalytic inactive, but it can associate with diverse 
chromatin-modifying proteins, HDAC1, HDAC2, G9a, PRMT5 and LSD1 for 
gene silencing during cell differentiation (Yu et al. 2000; Ancelin et al. 2006; 
Gyory et al. 2004; Su et al. 2009).  
 
1.10.2 Structures of PR and zinc finger domains  
The SET domain family shares two conversed signature motifs, 
H/RxxNHxC and ELxF/YDY, which are important for the catalytic activity (C 
Qian & Zhou 2006).  However, these motifs are not well conserved in PR 
domains (Wu et al. 2013). Crystal structures of some PR domains have been 
solved, but only the PRDM9 structure was solved in complex with the 
cofactor SAH and H3K4me peptide (Figure 1.7D). This structure provides the 
first example of the substrate and cofactor recognition by a PR domain. 
Asn320 in human PRDM9 is corresponding to the asparagine in H/RxxNHxC 
motif of the SET domain. The PRDM9 structure indicates that this residue is 
responsible for cofactor SAM binding, while it is not conserved in the 
catalytically active PRDM3, PRDM8 and PRDM16 (Wu et al. 2013). It still 
remains elusive how these PRDMs catalyze methylation.  
In PRDM9, a zinc knuckle motif precedes the core SET domain via a 
long linker to act as the pre-SET domain. This zinc knuckle motif also exists 
in PRDM4, PRDM6, PRDM7, PRDM10, PRDM11 and PRDM15 (Briknarová 
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et al. 2011). Beside this zinc knuckle, there is a zinc finger motif following the 
PR domain. In the crystal structure of mouse PRDM9 (amino acids 198-368), 
which is only composed of zinc knuckle and SET domain, the post-SET 
domain is disordered in the absence of substrate and cofactor but folds into a 
helix on the binding of substrate and cofactor (Wu et al. 2013). In contrast, the 
crystal structure of human PRDM9 (amino acids 195-415), which contains the 
zinc knuckle, PR domain and first zinc finger domain, has only been solved in 
the absence of substrate and cofactor. This zinc finger domain forms part of 
the post-SET domain in PRDM9 (195-415).  The PRDM9 post-SET domain is 
ordered but blocks the substrate-binding cleft and exposes the SAM binding 
site, which results in the autoinhibition of PRDM9 catalytic activity (Wu et al. 
2013). Enzymatic assays have also shown that the recombinant PRDM9 (195-
415) is less catalytically active in comparison with PRDM9 (198-368).  
Besides the pre-SET zinc knuckle and post-SET zinc finger, other 
zinc-finger motifs in PRDM protein may be involved in DNA binding or 
protein-protein interactions. Zinc-finger domains in some PRDM proteins 
(PRDM1, PRDM3, PRDM5, PRDM14 and PRDM16), have been shown to 
bind specifically to DNA. PRDM1 recruits histone lysine methyltransferase 
G9a through the first two zinc fingers and the proline-rich motif (Gyory et al. 
2004; Su et al. 2009).  Therefore, it is difficult to predict whether PRDM9 will 
be autoinhibited in context with the many zinc-finger domains.  
PRDM2 is a H3K9 methyltransferase and its PR domain structure was 
solved without substrate and cofactor (Kim et al. 2003; Briknarová et al. 2008) 
(Figure 1.7C). The pre-SET domain of PRDM2 is disordered, and the post-
SET domain forms an α-helix, but points away from the canonical active site 
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(Briknarová et al. 2008). It is possible that this post-SET domain would 
undergo conformational change upon the binding of substrate and cofactor due 
to its high mobility.  
 
1.11  FUNCTIONS OF HISTONE LYSINE METHYLATION  
With the advance of techniques, genome-wide scale of histone 
methylation, especially histone lysine methylation, has been characterized in 
mammals. Generally, transcription activation is associated with the 
H3K4me1/2/3, H3K36me3, H4K20me1, H2BK5me1 and H3K79me1/2/3 
marks, while transcription repression is correlated with H3K9me3, H3K27me3, 
and H4K20me3 (Black et al. 2012). For example, H3K4me3 is highly 
enriched on transcription start sites (TSS) (Barski et al. 2007). H3K4me3 can 
interact with different protein domains including WD40, MBT, and the plant 
homodomain (PHD). The PHD finger of TAF3 binds to H3K4me3 in order to 
recruit RNA polymerase II to mediate the regulation of transcription 
(Vermeulen et al. 2007). This interaction can be inhibited by asymmetric 
dimethylation of H3R2, but enhanced by acetylation of H3K9 and H3K14 
(Vermeulen et al. 2007). This cross-talk phenomenon has been found to be 
very common between histone modifications.  
 
1.12 PRDM9  
In mammals, meiotic recombination happens on a set of 1 to 2kb 
regions, termed hotspots and contributes to new combinations of alleles. The 
Prdm9 (also known as Meisetz) gene is a major player for hotspot 
specification in mouse and human (Baudat et al. 2010; Myers et al. 2010; Berg 
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et al. 2010). Prdm9 is a meiosis-specific gene that is only detected in testes 
and ovaries (Hayashi et al. 2005). Prdm9-null mice are sterile due to the 
impairment of the double-stranded break repair, deficient pairing of 
homologous chromosomes and impaired sex body formation (Hayashi et al. 
2005).  PRDM9 protein contains one Krüppel-associated box (KRAB) domain, 
a PR domain and a tandem array of C2H2 zinc-fingers. PRDM9 is a histone 
lysine methyltransferase that specifically trimethylates lysine 4 on histone 3 
(H3K4me3) by the PR domain (Hayashi et al. 2005). The function of the 
KRAB domain in PRDM9 is still unknown. The C-terminal array of PRDM9 
zinc-finger domains was revealed to bind to a degenerate hotspot 13-mer 
sequence (CCNCCNTNNCCNC) on DNA (Baudat et al. 2010). These zinc-
fingers differ in the numbers among individuals of a species and closely 
related species.  
In one study, Prdm9 was identified as one of cancer/testis (CT) genes 
that could be used as biomarker for cancer diagnostics and prognostics 
(Feichtinger et al. 2012). PRDM9 is expressed in some cancer cell lines, 
including NTERA, LoVo, PC-3, MCF-7, T1014, G361, COLO0800 and K562 
(Feichtinger et al. 2012). Rare allelic forms of PRDM9 have been found in 
children with B-cell precursor acute lymphoblastic leukemia (B-ALL) and in 
their parents (Hussin et al. 2013). These studies implicate the involvement of 
PRDM9 in human disease.  
 
1.13 PRDM15 
Human PRDM15 contains a PR domain, a zinc knuckle and 17 zinc 
fingers (Figure 1.8). It is still elusive whether this PR domain has enzymatic 
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activity. Recently, PRDM15 has been identified as a transcription factor that 
was overexpressed in human B cell lymphomas (Giallourakis et al. 2013), but 
there is no data to date describing its potential as an oncogene. Further studies 
on the function of the PR domain or zinc fingers, will provide the basic 
understanding of the biological functions of PRDM15.  
 
1.14 RATIONALE AND SIGNIFICANCE OF WORK 
The scope of my work is to study the biochemical properties and the 
substrates of PRMT5, PRDM9 and PRDM15 in order to further understand 
their biological functions. 
PRMT5 is the major type II protein arginine methyltransferase that can 
methylate histone and many non-histone proteins. Hence, it is essential to 
characterize the PRMT5 methylome and identify the novel substrates. The 
goal of this work is: (1) to characterize the complete PRMT5 methylome; and 
(2) to validate novel substrates and study the substrate specificity of PRMT5.  
PRDM9 was identified as a H3K4 histone lysine methyltransferase and 
it is important for meiotic recombination. However, the function and structure 
of the PRDM15 PR domain have not been studied. It is essential to perform 
functional and structural studies of the PRDM15 PR domain and to compare it 
with PRDM9. The goal of this work is: (1) to biochemically characterize the 
PRDM9 PR domain; (2) to know whether PRDM9 can methylate non-histone 
substrates; (3) to determine whether the PRDM15 PR domain has catalytic 
activity; and (4) to crystalize the PRDM15 PR domain.  
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CHAPTER 2  
MATERIALS AND METHODS 
 
2.1 VECTORS AND E. coli STRAINS 
The following vectors were used for cloning: pNIC28-Bsa4 and pFB-
LIC-Bse vectors contain an N-terminal His6 tag followed by a TEV (tobacco 
etch virus) protease cleavage site; pGEX-6P-1 vector (GE Healthcare Life 
Sciences) contains an N-terminal GST tag and human rhinovirus 3C protease 
cleavage site; pETDuet-1 vector has two multiple cloning sites with an N-
terminal His-tag in the first cloning site. DH5α and Top10 cells were used for 
molecular cloning. E. coli BL21 Star (DE3) (Invitrogen) was used for 
recombinant protein expression. 
 
2.2 ANTIBODIES 
6x-His epitope tag antibody HRP conjugate (Thermo Scientific) was 
used to detect recombinant His-tagged proteins on Western blots. The 
antibodies used for protein microarray were: symmetric di-methyl arginine 
motif [sdme-RG] (Cell Signaling, 13222), rabbit polyclonal pan-methyl 
antibody (Abcam, ab23366), and Alexa Fluor® 647 donkey anti-rabbit IgG 
(Invitrogen, A-31573). Other antibodies used in this study were Mono-R4-100 
(Cell Signaling, 8015S), Adme-R (Cell Signaling, 13522) and Asym24 




2.3 PROTEIN EXPRESSION AND PURIFICATION  
2.3.1 Expression and purification of the PRMT5-MEP50 complex 
Full length of human PRMT5 (GenBank® accession number 
NM_001039619.2) and MEP50 (GenBank® accession number NM_024102.2) 
were cloned into the baculovirus transfer vector pFB-LIC-Bse. Baculovirus 
expression was performed as previously described (Shrestha et al. 2008). 
Following coexpression of PRMT5 and MEP50, the Sf9 cells were harvested 
and the pellets were stored at -80 ºC until used. Frozen insect cell pellets of 
PRMT5-MEP50 were resuspended in lysis buffer (50 mM HEPES, pH 7.5, 
250 mM NaCl, 10% glycerol, 10 mM imidazole, 0.5 mM TCEP, 0.1% Triton 
X100, protease inhibitors (Roche)). The cells were lysed by sonication for 5 
min and clarified by centrifugation. The supernatant was applied to 2 ml of 
nickel beads (QIAGEN) and incubated for 2 h. Nickel beads were washed for 
three times with wash buffer (50 mM HEPES, pH 7.5, 250 mM NaCl, 10% 
glycerol, 30 mM imidazole, 0.5 mM TCEP) and eluted in 5 ml of elution 
buffer (50 mM HEPES, pH 7.5, 250 mM NaCl, 10% glycerol, 250 mM 
imidazole, 0.5 mM TCEP). The eluted protein was run on SDS-PAGE and 
applied to a HiPrep 26/60 Sephacryl S-300 column that had been equilibrated 
with gel filtration buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 10% 
glycerol, 2 mM DTT). The fractions containing PRMT5-MEP50 complex 




2.3.2 Expression and purification of histone proteins 
Plasmids encoding human histone H2A, H2B, H3 and H4 were 
obtained from Karolin Luger. Plasmids were transformed into E. coli BL21 
Star (DE3).  Bacteria were cultured in 2 x TY medium at 37 ºC, 200 rpm until 
the OD600 reached 0.4, and the protein expression was induced with IPTG 
(Golden Biotechnology) at a final concentration of 0.4 mM for 3 h. Bacteria 
were pelleted down by centrifugation and resuspended in wash buffer (50 mM 
Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM benzamidine, 1 mM beta-
mercaptoethanol). The histone purification protocol was established as 
previously described (Dyer et al. 2004). In brief, cell pellets were lysed and 
inclusion bodies were dissolved in 7 M guanidine HCl. The denatured histones 
were purified by size exclusion and ion exchange, and refolded in refolding 
buffer (2 M NaCl, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 10 mM beta-
mercaptoethanol). The refolded histones were further dialyzed to histone 
storage buffer (300 mM NaCl, 20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM 
DTT).  
 
2.3.3 Expression and purification of PRMT5 substrates and PRMT1 
Human HNRNPA1, HNRNPH1, HNRNPK, SFPQ, KHDRBS1 and 
CNBP genes were amplified from 293T cDNA and further cloned into the 
pGEX-6P-1 vector (GE Healthcare Life Sciences). Human PRMT1 and mouse 
Prmt4 genes were also cloned into the pGEX-6P-1 vector. All of these 
plasmids were transformed into E. coli BL21 Star (DE3). Bacteria were grown 
in LB medium at 37 ºC, 200 rpm until OD600 0.6, and induced with 0.4 mM 
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IPTG at 25 ºC for 5 h. Cells were harvested by centrifugation and resuspended 
in GST binding buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM DTT) 
and further lysed by sonication. The cell lysate was clarified by centrifugation 
and the supernatant was filtered through 0.4 µm syringe filter and applied to 5 
ml GSTrap FF column (GE Healthcare) on ÄKTAxpress system for affinity 
purification. GST-CNBP was eluted with GST elution buffer (50 mM Tris-
HCl, pH 8.0, 10 mM reduced glutathione) and frozen at -80 ºC. 
 
2.3.4 Expression and purification of PRDM9 and PRDM15 
The DNA sequence encoding mouse PRDM9 (amino acids 192-377) 
was subcloned from Prdm9 (GenBank® accession number BC012016) into the 
pNIC28-Bsa4 vector. The DNA sequence encoding human PRDM9 (amino 
acids 195-385) was subcloned from 293T cDNA into the pETduet-1 vector 
(EMD Biosciences). DNA sequence encoding human PRDM15 (amino acids 
302-537) was subcloned from PRDM15 (GenBank® accession number 
NM_001040424.2) into the pETduet-1 vector. Plasmids were transformed into 
E. coli BL21 Star (DE3). Bacteria were grown in LB medium at 37 ºC, 200 
rpm until OD600 0.6, and induced with 0.4 mM IPTG at 16 ºC overnight. 
Bacteria were harvested and resuspended in His-binding buffer (50 mM Tris-
HCl, pH 8.0, 500 mM NaCl, 30 mM imidazole). Proteins were affinity 
purified using a HisTrap HP 5 ml column (GE Healthcare), eluted in His-
elution buffer (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 500 mM imidazole) 
and further purified by HiLoad 16/60 Superdex 75 column pre-equilibrated 





2.3.5 Expression and purification of PRDM15 (29-174) for 
crystallization  
The gene encoding mouse PRDM15 (amino acids 29-174) was 
subcloned from Prdm15 (GenBank® accession number XM_006522869.2) 
into the pNIC28-Bsa4 vector. Plasmid was transformed in E. coli BL21 Star 
(DE3) and protein expression followed the same protocol as 2.3.4. The 
bacterial pellet was resuspended in His-binding buffer (50 mM Tris-HCl, pH 
8.0, 500 mM NaCl, 30 mM imidazole) and lysed by sonication. The cell lysate 
was clarified by centrifugation, and the supernatant was filtered and passed 
through a HisTrap HP 5 ml column in ÄKTAxpress system for affinity 
purification. His-PRDM15 was eluted with His-elution buffer (50 mM Tris-
HCl, pH 8.0, 500 mM NaCl, 500 mM imidazole) and further dialyzed to His-
binding buffer overnight. The histidine tag of PRDM15 was cleaved off with 
His-TEV protease for overnight. The protein was applied to a HisTrap HP 5 
ml column for second affinity purification. PRDM15 was collected from the 
flow through and concentrated for size-exclusion chromatography using a 
HiLoad 16/60 Superdex 75 column with pre-equilibrated with gel filtration 
buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl). 
 
2.4 SITE DIRECTED MUTAGENESIS  
Mutant CNBP and PRDM9 constructs were generated using a KOD 





2.5 IN VITRO RADIOACTIVE METHYLATION ASSAY  
Recombinant proteins were incubated with 17.3 µM of S-adenosyl-L-
[methyl-14C]- methionine (PerkinElmer) and enzyme in methylation buffer (50 
mM Tris-HCl, pH 8.0, 20 mM KCl, 5 mM MgCl2 and 2 mM DTT, 10% 
glycerol) at 30 ºC for 2 h. The samples were run on SDS-PAGE, dried and 
exposed to a phosphor screen for 3 days.  
 
2.6 ISOLATION AND CULTURE NEURAL PROGENITOR CELLS 
(NPCS) 
4-OHT-inducible conditional knockouts were created by crossing 
PRMT5F/F mice to the ROSA26:CreERt2 (ER) mice (Bezzi et al. 2013). To 
isolated neural stem cells, E14.5 mice embryos were harvested, and their 
cortices were carefully dissected in ice-cold PBS and incubated with trypsin 
(Invitrogen) for 10 min at 37 °C. The tissue was then mechanically 
dissociated, and single cells were cultured into complete NPC medium 
containing DMEM (Life Technologies), 2% B-27 (Life Technologies), 1% 
penicillin/streptomycin (Life Technologies), 20 ng/ml recombinant human 
epidermal growth factor (EGF) (Peprotech), and 20 ng/ml recombinant human 
fibroblast growth factor-basic (FGF-2) (Peprotech). Neural stem cells were 
subcultured every 4 days. On day 0, 3 x 105 of cells were seeded in a T75 flask 
with 12 ml of fresh medium. On day 2, NPCs were transferred into a new T75 
flask and 6 ml of fresh medium was added. Neurospheres were split on day 4 
for the next culture passage. To delete PRMT5, PRMT5F/F NPCs were treated 
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with either 50 nM 4-hydroxytamoxifen (4-OHT) (Sigma) or the equivalent 
volume of ethanol on day 3, and split after 24 h.  
 
2.7 HEAVY METHYL SILAC FOR NPCS 
SILAC DMEM lacking methionine (PAA) was supplemented with 2% 
B-27, 1% penicillin/streptomycin, 20 ng/ml EGF, and 20 ng/ml FGF-2. Heavy 
SILAC DMEM medium was further supplemented with [13CD3] methionine, 
while the light medium was added with normal methionine [12CH3]. NPCs 
were subcultured in hmSILAC light and heavy medium following the protocol 
in section 2.6. NPCs were washed with PBS, harvested and subjected to urea 
protein extraction. Heavy and light samples were mixed 1:1 and resolved by 
SDS-PAGE. The gel was stained with colloidal Coomassie stain and divided 
into slices. The gel slices were destained by adding gel destaining solution 
(50% v/v absolute ethanol in 50 mM ammonium bicarbonate), reduced with 
reduction buffer (10 mM DTT in 50 mM ammonium bicarbonate) for 1 hour 
at 56 °C and alkylated (55 mM iodoacetamide in 50 mM ammonium 
bicarbonate) for 45 min at room temperature. Subsequently, samples were 
dehydrated with 100% ethanol and washed with 50 mM ammonium 
bicarbonate. Next, the gel slices were digested using trypsin or chymotrypsin 
(12.5 ng/µl in 50 mM ammonium bicarbonate) at 37 ˚C, overnight. Peptide 
digests were made to 1% trifluoroacetic acid (TFA) to stop the digestion and 
digested peptides were extracted with extraction buffer (30% acetonitrile 
(ACN)/3% TFA). Peptide digests were dried on a vacuum evaporator, desalted 
and concentrated with C18 StageTips and further eluted in StageTip buffer B 
(80% ACN/0.1% TFA). Eluted peptides were dried by vacuum centrifugation 
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and resuspended in StageTip buffer A (5% ACN/0.1% TFA). Digested 
peptides were analyzed by MS for protein identification and quantification. 
MS data were processed using MaxQuant v1.5.2.8.  
 
2.8 IMMUNOBLOTTING  
Protein samples were separated on a 4-12% gradient polyacrylamide 
gel (Life Technologies) and transferred to a nitrocellulose membrane (Bio-rad) 
using a semi-dry system (Bio-rad). The transferred membranes were blocked 
in 5% skim milk (Sigma), probed with primary antibody and followed by 
secondary antibody, which was conjugated with horseradish peroxidase.  
2.9 IN VITRO METHYLATION ON ProtoArray® MICROARRAY  
ProtoArray® human protein arrays (Life Technologies) were thawed 
on ice for 15 minutes, then blocked with 1% BSA at 4 °C for 2 h in 4 well 
plate. After blocking, arrays were incubated with a reaction mixture containing 
20-50 ng/µl of enzyme and 300-200 µM SAM in methylation buffer (50 mM 
Tris-HCl, pH 8.0, 20 mM KCl, 5 mM MgCl2, 2 mM DTT, 10% glycerol) in 4 
well plate on a rotating tube shaker at 30 °C for 2 h. Arrays were washed three 
times with PBS-T in a 50 ml falcon tube, followed by another three washes 
with PBS-T plus 1% BSA. Arrays that were probed with either sdme-RG or 
rabbit polyclonal pan-methyl antibody were diluted in PBS-T with 1% BSA 
for overnight at 4°C or 1 h at room temperature. Arrays were washed three 
times with PBS-T plus 1% BSA and further incubated with Alexa Fluor® 647 
donkey anti-rabbit IgG diluted in PBS-T with 1% BSA for 1 h at room 
temperature. Arrays were washed five times with PBS-T followed by one 
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wash with deionized water, then dried using a 50 ml falcon tube at 200 x g for 
1 min. Arrays were scanned using Axon GenePix 4000B (Molecular Devices), 
and data were analyzed for each block using Genepix Pro 6.1 software 
(Molecular Devices). 
 
2.10 ISOTHERMAL TITRATION CALORIMETRY (ITC) 
ITC experiments were performed using a MicroCal Auto-iTC200 
instrument (GE Healthcare) at 25 ˚C in gel filtration buffer (20 mM HEPES, 
pH 7.5, 50 mM NaCl). Based on the binding affinities of the ligands, 0.05 mM 
enzyme was loaded in the cell with either 1.0 mM or 2.5 mM of ligand in the 
titrating syringe. For the enzyme–substrate complex, 500 µM of H3 peptide 
(1–21) was loaded in the cell by the side of the enzyme. A total of 20 
injections were performed with a spacing of 120 s between each injection. 
Mixing enthalpies from titrant solution injections into protein-free ITC buffer 
were subtracted from all data to correct for the heat of dilution. Data were 
analyzed using Origin 7.0 software (Origin Lab Corporation), and the binding 
affinity was calculated using a one-site binding model. 
 
2.11 CRYSTALLIZATION OF mPRDM15 (29-174) 
Purified mPRDM15 (29-174) was concentrated to 15 mg/ml and 
crystallized using hanging drop vapor diffusion method by mixing 1 µl of 
protein solution with 1 µl of reservoir solution. Crystallization plates were 







 IDENTIFYING NOVEL SUBSTRATES FOR PROTEIN 
ARGININE METHYLTRANSFERASE 5 
 
3.1 DYNAMIC CHANGES OF METHYLATED ARGININE 
RESIDUES UPON THE DELETION OF PRMT5 
PRMT5 has been shown as an essential regulator of splicing in 
mammals (Bezzi et al. 2013). Selective deletion of PRMT5 in neural 
stem/progenitor cells (NPCs) results in the postnatal death in mice, and the 
significant reduction in the number of primary neurospheres and the total 
number of cells in neurospheres (Bezzi et al. 2013). Moreover, deletion the 
Prmt5 gene on Prmt5F/F ER NPC cells by OHT treatment leads to the reduced 
arginine methylation on Sm proteins, to malfunction of the constitutive 
splicing machinery and to alternative splicing events (Bezzi et al. 2013). In 
this study, Prmt5F/F ER NPC cells were used to study the dynamic changes of 
arginine methylation by PRMT5. The global loss of symmetric arginine 
dimethylation was observed on Prmt5F/F ER NPC cells after 4 days of OHT 
treatment (Figure 3.1). Also, the monomethylation was decreased in some 
proteins. Interestingly, the loss of symmetric arginine dimethylation does not 




Figure 3.1 PRMT5 loss leads to the decrease in mono- and symmetric di-
methylation of arginine sites in NPCs. (A) PRMT5 was assessed in Prmt5F/F 
ER NPC cells after 4 days of EtOH (E) or OHT (O) treatment.  (B) The 
dynamic changes of mono-methylated (Mono-R4-100), symmetric-
dimethylated (Sdme-RG) and asymmetric-dimethylated (Adme-R and 
Asym24) arginine residues in the presence (E) or absence (O) of PRMT5.  
 
Stable isotope labeling by amino acids in cell culture (SILAC) is an in 
vivo metabolic labeling strategy that enables relatively accurate quantification 
of specific isotope amino-acid residues. This technique, together with liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), has been widely 
employed in multiple applications, including global protein expression, 
protein-protein interactions and dynamic changes of PTMs (Chen et al. 2015). 
Heavy methyl SILAC (hmSILAC) has been employed both to identify and 
quantify in vivo methylation sites using [12CH3] (light) or [13CD3] methionine 
(heavy) (Ong et al. 2004). Heavy methionine is incorporated into proteins 
during cell growth. It is also metabolically converted into heavy SAM, which 
serves as the methyl donor in cells.  
In this work, to identify new high-confidence methylated sites for 
PRMT5, we utilized hmSILAC in combination with high resolution LC-
MS/MS analysis on NPCs derived from wild type or PRMT5 knockout mice 
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(Figure 3.2). The Prmt5F/F ER NPC cells were cultured in heavy and light 
medium for four passages for the incorporation of heavy methionine. After the 
stable isotope labeling, the Prmt5F/F ER NPC cells on heavy and light medium 
were treated with EtOH and OHT for one day. Another set of Prmt5F/F ER 
NPC cells were treated with OHT and EtOH. The WT and PRMT5 -/- NPCs 




Figure 3.2 Flowchart describing the steps of identifying novels substrates for 
PRMT5 using hmSILAC. WT and PRMT5 knockout NPCs were grown in 
heavy and light medium, respectively (experiments 1a, 1b, and 1c). To ensure 
the reproducibility of the results, the hmSILAC labeling was also performed in 
a reversed set-up (experiment 2a and 2b). Heavy and light samples were 
mixed in a 1:1 ratio, and subjected to in-gel digestion with trypsin and 
chymotrypsin.  The digested samples were analyzed using two fragmentation 
methods: HCD and CID. The acquired data were processed using a 
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combination of publically available software MaxQuant and scripts developed 
in-house to identify methylated sites.  
 
The heavy WT and light PRMT5 knockout samples were digested with 
trypsin and chymotrypsin, and subjected to MS analysis using the 
fragmentation methods HCD and CID on experiments 1a, 1b, and 1c (Figure 
3.2). The samples on reverse set-up were only digested with trypsin and 
subjected to MS analysis by HCD and CID on experiments 2a and 2b (Figure 
3.2). The hmSILAC data were processed using a combination of software 
MaxQuant and scripts developed in-house. Log2(heavy/light ratio) was 
calculated for all five experiments. The down-regulated arginine methylation 
upon the deletion of PRMT5 are indicated by log2(heavy/light ratio) >0 on 
experiments 1a, 1b, and 1c, and log2(heavy/light ratio) <0 on experiments 2a 
and 2b.  We identified 154 methylated arginine sites (including 
monomethylated and dimethylated arginines) from 81 proteins.  Many of these 
proteins have the RNA, DNA or ATP binding ability (Table 3.1).  In particular, 
there are 14 proteins that are participating in RNA splicing (Table 3.2) and 
interacting with each other (Figure 3.3), especially the heterogenous nuclear 
ribonucleoproteins (hnRNPs). The hnRNP proteins are participating in many 
RNA processes, including pre-mRNA splicing, mRNA export, localization, 
translation, and stability. 
Table 3.1 The molecular functions of the proteins identified in hmSILAC 
Molecular function Count 
RNA binding 27 
DNA binding 13 




Table 3.2 The biological processes of the proteins identified in hmSILAC  
Biological process Count 
RNA splicing 14 
Transcription 12 
Protein transport 7 
RNA transport 3 
 
 
Figure 3.3 The protein-protein interactions between the RNA splicing proteins 
from hmSILAC. STRING was used to analyze the protein-protein interactions.  
 
In this hmSILAC dataset, most of the identified arginine residues are 
found on the arginine-glycine-rich sequences (which are also referred to as 
RGG/RG motifs). Majority of these arginine residues were found to be down 
regulated with the loss of PRMT5 (Table 3.3, Table A1 in Appendix section). 
However, there are some up-regulated arginine sites, which could be due to 
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the indirect effects of other PRMTs. For example, the arginine methylation of 
R289, R291 and R302 on KHDRBS1 was up regulated upon the loss of 
PRMT5. It indicates that the arginine methylations of these sites were 
compensated by other PRMTs. The RGG/RG motifs are commonly found on 
many RNA binding proteins. Since PRMT5 is known to methylate RGG/RG 
motif-containing proteins, it is not surprising to find among these putative 
PRMT5 substrates, there was a strong enrichment of splicing proteins, 
including hnRNPA1, hnRNPH1, hnRNPK. Some targets, such as hnRNPA1, 
hnRNPK, SFPQ, KHDRBS1, and CNBP, had been already reported as 
PRMT1 substrates. RSP10, a known PRMT5 substrate, was also identified in 







Table 3.3 Methylated arginines identified in hmSILAC of WT and PRMT5 
KO NPCs.  Heavy WT and light PRMT5 -/- samples were analyzed using 
HCD (1a), CID (1b), and HCD (1c). Heavy PRMT5-/- and light WT samples 
were analyzed by HCD (2a) and CID (2b). Intensity log2 (heavy/light ratio) 





symbol Modified sequence Site 1a 1b 1c 2a 2b 
P53996 CNBP SR(di)GR(di)GGFTSDR 34 1.47   2.05 -2.22   
P53996 CNBP SR(di)GR(di)GGFTSDR 32 1.47   2.05 -2.22   
P53996 CNBP ECPTGGGR(di)GR(di)GM(ox)R 25 1.38   1.56     
P53996 CNBP ECPTGGGR(di)GR(di)GM(ox)R 27 1.38   1.56     
P53996 CNBP ECPTGGGR(di)GR(di)GMR 25       -2.05   
P53996 CNBP ECPTGGGR(di)GR(di)GMR 27       -2.05   
Q5EBP8 hnRNPA1 GGNFSGR(me)GGFGGSR(me) 225 1.21   1.19 -2.77   
Q5EBP8 hnRNPA1 GGNFSGR(me)GGFGGSR(me) 232 1.21   1.19 -2.77   
Q5EBP8 hnRNPA1 
SGSGNFGGGR(di)GGGFGGND 
NFGR 206 1.11 1.31   -2.20 -2.42 
Q5EBP8 hnRNPA1 
SGSGNFGGGR(me)GGGFGGNDN
FGR(me) 218       -2.32   
Q5EBP8 hnRNPA1 
SGSGNFGGGR(me)GGGFGGNDN
FGR(me) 206       -2.32   
Q5EBP8 hnRNPA1 QEMASASSSQR(me) 194         -2.37 
Q5EBP8 hnRNPA1 
SGSGNFGGGR(di)GGGFGGND 
NFGR(di)GGNFSGR(di)GGFGGSR 218         -1.55 
Q5EBP8 hnRNPA1 
SGSGNFGGGR(di)GGGFGGND 
NFGR(di)GGNFSGR(di)GGFGGSR 206         -1.55 
Q5EBP8 hnRNPA1 
SGSGNFGGGR(di)GGGFGGND 
NFGR(di)GGNFSGR(di)GGFGGSR 225         -1.55 
O35737 hnRNPH1 PGAGR(di)GYNSIGR(di)GAGFER 224 2.56 3.40 3.05 -2.47   
O35737 hnRNPH1 PGAGR(di)GYNSIGR(di)GAGFER 217 2.56 3.40 3.05 -2.47   
O35737 hnRNPH1 (ac)M(ox)LSTEGR(me)EGFVVKVR 8         -4.05 
O35737 hnRNPH1 
R(di)GAYGGGYGGYDDYGGYND
GYGFGSDR 233  -2.83   1.81 
O35737 hnRNPH1 
R(me)GAYGGGYGGYDDYGGYN
DGYGFGSDR(me) 259  -2.83   1.81 
J3QNY1 hnRNPK QEMQSAGSQR(me) 192   0.42  -3.29 
P61979 hnRNPK PVGFPMR(di)GR(di)GGFDR 187 0.65   -1.37  
P61979 hnRNPK PVGFPMR(di)GR(di)GGFDR 189 0.65   -1.37  
Q60749 KHDRBS1 PR(di)GGGGGPR(di)GGAR 52 1.05 -1.25 1.18   -2.06 
Q60749 KHDRBS1 PR(di)GGGGGPR(di)GGAR 45 1.05 -1.25 1.18   -2.06 
Q60749 KHDRBS1 
GVSVR(di)GR(di)GAAPPPPPVPR(
di) 289 -2.16 -2.22 -1.67 0.51 1.37 
Q60749 KHDRBS1 
GVSVR(di)GR(di)GAAPPPPPVPR(
di) 291 -2.16 -2.22 -1.67 0.51 1.37 
Q60749 KHDRBS1 
GVSVR(di)GR(di)GAAPPPPPVPR(
di) 302 -2.16 -2.22 -1.67 0.51 1.37 
Q8VIJ6 SFPQ SR(di)GGGGGGFHR 9 1.42 1.35 1.18 -1.37   
Q8VIJ6 SFPQ R(di)GGGGGR(di)GGLHDFR 19 1.45 -0.97 1.00 -1.43 1.14 
Q8VIJ6 SFPQ R(di)GGGGGR(di)GGLHDFR 25 1.45 -0.97 1.00 -1.43 1.14 
Q8VIJ6 SFPQ FR(di)SR(di)GGGGGGFHR 9   1.48 -1.31     






3.2 IDENTIFICATION OF NOVEL SUBSTRATES FOR PRMT5 
USING ProtoArray® MICROARRAY APPROACH  




Figure 3.4 Fluorescence-based detection approach to profile protein 
methyltransferase substrates on the ProtoArray® microarray system. The 
schematic diagram describes the steps of protein methyltransferase substrate 
profiling. The protein microarray was first blocked with BSA, incubated with 
enzyme and SAM, further probed with the antibody that can recognize the 
methylated substrates, and followed by the Alexa fluor® 647 secondary 
antibody.  
 
ProtoArray® Human Protein Microarray contains more than 9,000 
human proteins printed in duplicates on a nitrocellulose-coated glass slide. 
The ProtoArray® microarray can be used to profile protein-protein 
interactions, enzyme substrates, small molecule-protein interactions, immune 
response biomarkers and antibody specificity. Specifically, ProtoArray® 
microarray has been applied to identify the novel PKMT substrates by 
fluorescence-based (Figure 3.4) and radioactive-based detection approaches 
(Levy et al. 2011). Therefore, we also utilized ProtoArray microarray system 




3.2.2  Recombinant PRMT5-MEP50  
 
 
Figure 3.5 PRMT5-MEP50 complex is more active than PRMT5. (A) 
Analysis of small-scale purification of PRMT5 and PRMT5-MEP50 complex 
by SDS-PAGE gel stained with Coomassie blue and Western blot with an 
antibody against the His-tag.  Both PRMT5 and MEP50 genes were fused with 
an N-terminal His-tag. (B) In vitro methylation activity of PRMT5 and 
PRMT5-MEP50 complex on histone H2A. Western blot against His-tag was 
used to detect the amount of PRMT5 in each reaction.  
 
In order to perform the PRMT5 substrate profiling with protein 
microarray, the recombinant PRMT5-MEP50 complex was purified from Sf9 
cells. The crystal structure of human PRMT5 has been solved in complex with 
its binding partner MEP50, the SAM analog A9145C and H4 peptide 
(Antonysamy et al. 2012). Binding partner MEP50 stimulates PRMT5 
catalytic activity (Antonysamy et al. 2012; Ho et al. 2013). It has been shown 
that PRMT5 alone forms a dimer in solution, but tend to aggregate 
(Antonysamy et al. 2012). We tried to express human PRMT5 alone and in 
combination with MEP50 in insect cells on a small scale, and utilized different 
amounts of PRMT5 for methylation. As shown in Figure 3.5, the PRMT5-
MEP50 complex showed a higher methyltransferase activity than PRMT5. 
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The enzymatic difference of PRMT5 and PRMT5-MEP50 complex was due to 
their different binding affinities for the substrate and cofactor SAM 
(Antonysamy et al. 2012).  In large-scale purification, the PRMT5-MEP50 
complex was purified by affinity and gel filtration chromatography (Figure 
3.6A). The catalytic activity of PRMT5-MEP50 was tested on recombinant 
histones H2A, H2B, H3 and H4 (Figure 3.6B). Purified PRMT5-MEP50 can 




Figure 3.6 Analysis of purified recombinant human PRMT5-MEP50 complex. 
(A) PRMT5-MEP50 complex was purified by nickel affinity and gel filtration 
chromatographies. The purity of PRMT5-MEP50 was analyzed on a SDS-
PAGE gel. (B) In vitro methylation activity of PRMT5-MEP50 was checked 
on histones H2A, H2B, H3 and H4. 200 nM PRMT5-MEP50, 10 µM histone 
and 17.3 µM 14C-SAM were included in each reaction. These reactions were 
incubated at 30 ˚C for 2 h.   
 
3.2.3  PRMT5 substrate profiling with ProtoArray® microarray 
To profile PRMT5 substrates, we chose the fluorescence-based 
approach as the detection method for the on-chip methylation assay (Figure 
3.4). This array-based approach was combined with antibody detection using 
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symmetric di-methyl arginine motif [sdme-RG] (Cell Signaling, 13222), 
which is the mixture of several monoclonal antibodies with the high 
specificity to symmetrically dimethylated arginine, but not to non-methylated 
and other methylated arginines. To test the specificity of this antibody, a 
Western blot was performed on the unmodified and symmetrically methylated 
histone H2A. As shown in Figure 3.7A, this antibody specifically detects 
symmetrically dimethylated H2A. To identify the novel substrates for PRMT5, 
two experimental arrays were performed with reactions containing PRMT5, 






Figure 3.7 Substrate profiling of PRMT5 substrates on ProtoArray® 
microarray system. (A) A Western blot was performed on unmodified and 
symmetrically methylated H2A using sdme-RG (CST #13222). (B) In vitro 
methylation assay of PRMT5-MEP50 complex on the protein microarray. 
Scanned images of negative control and PRMT5 arrays. Reaction containing 
200 nM of PRMT5-MEP50 complex and 300 µM SAM was incubated with 
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the protein arrays for three hours at 30 ˚C for 3 h. The arrays were incubated 
with the sdme-RG antibody at 4 ˚C for overnight and with Goat anti-rabbit 
IgG (Alexa Fluor ® 647) at room temperature for 1 h. (C) Hits selected from 
negative control and PRMT5 arrays were overlapped using Venny 2.0.  
 
The data analysis used here is different from the method that Levy et 
al. 2011 described. Raw data generated from Genepix Pro 6.1 software were 
further analyzed by Prospector (Invitrogen) to calculate the Z-Factor, the Z-
Score and spot CV. The Z-Factor is a measure of the signal to noise ratio of 
the each signal. The Z-Score is a measure of the signal of a particular protein 
relative to the signals from all protein features on the same array, in units of 
standard deviations. The spot CV indicates the coefficient of variance of the 
signal. Hits were selected from control and experimental arrays based on these 
three parameters at the thresholds: Z-Factor > 0.35, Z-Score > 3, and spot CV 
< 0.5) (Figure 3.7C). The overlap of the hits from experimental and control 
arrays resulted in having 33 hits on the two PRMT5 arrays and 39 hits on the 
control and PRMT5 arrays. These 33 and 39 hits were further filtered based on 
the signal ratio of experimental and control array > 1.5.  
 
3.2.4 Targets identified only in the PRMT5 arrays 
All 33 hits identified from the two PRMT5 arrays have signal ratios 
greater than 1.5. Magnified images for the duplicate spots of 10 selected hits 
are shown in Figure 3.8. Some of these hits contain the RGG/RG-rich motifs, 
while others do not possess this motif (Table 3.4). It is possible that the hits 
without RGG/RG-rich motifs may be caused by the non-specific binding of 
sdme-RG antibody after the overnight incubation. Therefore, future validation 
will be needed for these hits. SERPINE1 mRNA binding protein 1 (SERBP1), 
an RGG/RG motif-containing protein, shows up as the top target for PRMT5. 
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We noticed that there are four isoforms of SERBP1 included on protein array, 
which are all identified as a target for PRMT5 (Table 3.4 - 3.5). SERBP1 has 
been reported as substrate of PRMT1 (Lee et al. 2012). The subcecullar 
localization of SERBP1 is mainly in the cytoplasm. Interestingly, inhibition of 
arginine methylation by Adox or PRMT1 depletion increased its nuclear 
distribution (Lee et al. 2012). It would be interesting to know whether the 






Table 3.4 Z-scores of 33 putative targets from two PRMT5 arrays. Proteins 
with RGG/RG motif were shown in light gray background.  
 





NM_015640.1 SERBP1 2.92 10.98 9.63 GRG 
BC022893.1 KCTD6 -0.03 10.20 9.80  
NM_006153.3 NCK1 2.32 9.05 5.95  
NM_023930.1 KCTD14 0.01 7.54 5.79 GRF 
BC011498.1 HDAC6 0.48 6.79 8.32  
NM_007362.2 NCBP2 0.03 6.77 8.01 GRG 
NM_006272.1 S100B 0.86 6.39 6.13 GRE 
BC030950.1 PRAC 2.81 5.20 5.30 GRG 
NM_003302.1 TRIP6 1.23 4.79 8.04 GRG 
BC000393.1 FAM127B 2.47 4.58 5.55 GRG 





0.16 4.54 5.03 HRG, DRG 
NM_030778.1 CYFIP2 0.09 4.25 4.40 ARG, ERG 
BC004969.1 cDNA clone IMAGE:2906290 -0.11 4.18 4.74 
GRC 
ERG 
NM_198086.1 JUB -0.08 4.11 4.76  
PV3314 MAPK1 0.37 4.02 3.02 VRG, LRG 
BC031057.1 RCHY1 -0.10 3.92 3.27 GRH 
NM_006294.2 UQCRB -0.09 3.91 3.37  
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BC031469.1 hypothetical LOC554207  -0.07 3.90 6.09  
BC015091.2 CAPN1 0.52 3.89 3.79  
BC001694.1 UBE2B 0.15 3.73 4.82 GRQ 
BC002680.1 TRIP6 0.34 3.49 5.11 GRG 
BC004369.1 APP -0.11 3.43 4.99 GRK GRL 
NM_032662.1 hypothetical MGC10600  -0.09 3.38 3.84  










0.76 3.25 4.06 KRG, GRE 
NM_033387.2 FAM78A 0.04 3.25 3.38  
NM_001011700.1 MCCD1 -0.11 3.22 5.03  
BC052955.1 WASL 0.18 3.20 3.10 GRG 
NM_133627.1 RAD51D -0.06 3.15 4.04  
NM_020664.3 DECR2 0.99 3.13 4.10 GRR, GRI 
NM_000269.1 NME1 -0.03 3.08 3.01 GRV, GRN 





Figure 3.8 Magnified images for 10 putative targets from two PRMT5 arrays. 
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Thyroid hormone receptor interactor 6 (TRIP6) is another putative 
target for PRMT5 with two isoforms passing all the thresholds (Table 3.4). 
TRIP6 has not been reported as substrate for any PRMT enzymes. TRIP6 is a 
scaffolding protein with multiple domains that mediate various protein-protein 
interactions. TRIP6 plays important roles in cytoskeletal organization, cell 
motility and antiapoptotic signaling (Lin & Lin 2011). TRIP6 contains 
proline-rich domains in the N-terminal region and three LIM domains in the 
C-terminal region. The RGG/RG motif of TRIP6 localizes in the proline-rich 
region. It would be interesting to investigate the functional roles of arginine 
methylation of TRIP6 by PRMT5.  
 
 
3.2.5 Targets identified in control and PRMT5 arrays 
There are 39 hits that overlap between the control and PRMT5 arrays, 
which might due to non-specific binding of the primary and secondary 
antibodies. For these 39 hits, the signal ratio of PRMT5 to control was further 
used to filter at the threshold 1.5, leading to a subset of 13 additional putative 
targets (Table 3.5, Figure 3.9). One possible explanation for the large number 
of control hits is that the antibody used may have non-specific binding to 
proteins containing RGG/RG-rich sequences. Most of the 13 hits are RGG/RG 
motif-containing proteins. For example: cellular nucleic acid-binding protein 
(CNBP) has a signal ratio of 1.95 and can be considered as putative target of 
PRMT5. This protein has also been identified in our hmSILAC dataset. 
KHDRBS2 is a positive hit in this protein microarray system and KHDRBS1 
is in the SILAC dataset. The protein microarray only includes KHDRBS2 and 
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KHDRBS3 isoforms, but not KHDRBS1. Both of KHDRBS1 and KHDRBS2 
contain a similar RGG/RG motif.  
 
Table 3.5 13 putative targets for PRMT5 filtered via signal ratio. Proteins with 
RGG/RG motif were shown in light gray background.  
 







BC020555.1 SERBP1 3.41 3.51 3.46 GRG 
BC015886.1 RGMA 2.49 3.41 2.95 GRG 
BC017114.1 OBFC2A 2.67 2.32 2.49 GRG 
RNP_COMPLE
Xb RNP_COMPLEX 2.54 2.41 2.47  
BC002488.1 SERBP1 2.26 2.28 2.27 GRG 
BC003049.1 SERBP1 2.44 1.93 2.18 GRG 


















Smithb Smith 1.90 1.45 1.68  
NM_022076.2 DUSP21 1.29 1.92 1.60 GRT 
BC022325.1 PHC3 1.62 1.55 1.58 GRP 
NM_152688.1 KHDRBS2 1.55 1.54 1.54 GRG 
a Arginine residues containing a glycine residue before or after were shown in table.  






Figure 3.9 Magnified images for putative targets of PRMT5 on the overlap 
region of control and two PRMT5 arrays.  
 
Surprisingly, hnRNPA1, hnRNPH3, hnRNPK and histone H2A 
(HIST1H2AC) were not picked up as positive hits on the protein microarray 
(Table 3.6-3.7, Figure 3.10).  Although they all have signal ratio above 1.5, 
their Z-scores are too low to pass the set threshold. That also means that they 
are not the top and strongest hits in the whole protein array, although they 
have increased signal on PRMT5 arrays. We also noticed that the sdme-RG 
antibody could strongly recognize coilin, RSP10 and LSM4 in the negative 
control array, again confirming the cross-reactivity with proteins containing 
RGG/RG motifs. However, the arginine methylations on coilin, RSP10 and 




Table 3.6 Signal ratios of hnRNPA1, hnRNPK, hnRNPH3, and three known 
PRMT5 substrates on protein arrays 
 
















NM_002136.1 hnRNPA1 2734.5 7313.5 12940 2.67 4.73 3.70 
NM_031262.1 hnRNPK 1124 3347 5771.5 2.98 5.13 4.06 
NM_021644.2 hnRNPH3 1755 3913 5276.5 2.23 3.01 2.62 
NM_003512.3 HIST1H2AC 381.5 2269 4791 5.95 12.56 9.25 
NM_004645.1 Coilin 65387.5 63488.5 50490.5 0.97 0.77 0.87 
NM_001014.2 RPS10 65208 62436 63576 0.96 0.97 0.97 
 
         
 
 
Table 3.7 Z-Scores of hnRNPA1, hnRNPK, hnRNPH3, and three known 
PRMT5 substrates on protein arrays 
          





NM_002136.1 hnRNPA1 0.69 0.63 1.25 
NM_031262.1 hnRNPK 0.20 -0.12 0.03 
NM_021644.2 hnRNPH3 0.39 -0.01 -0.06 
NM_003512.3 HIST1H2AC -0.03 -0.32 -0.14 
NM_004645.1 Coilin 20.04 11.26 7.66 
NM_001014.2 RPS10 19.99 11.06 9.90 
 





Figure 3.10 Magnified images of negative hits: hnRNPA1, hnRNPK, 





3.3 IN VITRO VALIDATION OF NOVEL SUBSTRATES FOR 
PRMT5 
Next, hnRNPA1, hnRNPH1, hnRNPK, SFPQ, KHDRBS1 and CNBP 
were selected for further validation in vitro. hnRNPA1, hnRNPK, SFPQ, 
KHDRBS1 and CNBP were substrates for PRMT1 (Liu & Dreyfuss 1995; 
Yang et al. 2014; Snijders et al. 2015; Bedford 2003; Wei et al. 2014). The 
dynamic changes of arginine methylation on these five proteins were 
identified in our hmSILAC experiment. CNBP is a substrate identified with 
both the hmSILAC and the ProtoArray® microarray system. These genes were 
cloned into the pGEX-6p-1 vector, and the recombinant proteins were 
expressed in BL21 (DE3) and purified using GST column. Methylation assays 
on these recombinant proteins prove that these proteins can be methylated by 
both PRMT5-MEP50 and PRMT1 in vitro (Figure 3.11). GST-SFPQ (1-57) 
can be methylated by both PRMT5 and PRMT1, whereas GST-SFPQ (298-
707) can only be methylated by PRMT5, but not by PRMT1. Thus, PRMT5 
and PRMT1 seem to have different substrate specificity.  
Synthetic unmodified and pre-methylated peptides from these six 
targets were also used in the methylation assay to further confirm the 
identified peptide sequences and arginine residues from hmSILAC (Figure 
3.12). All the unmodified peptides can be actively methylated by PRMT5.  
The pre-methylated peptides with certain methylated arginines cannot be 
methylated by PRMT5, except KHDRBS1-asym peptide. That is because the 
only one unmodified arginine on the KHDRBS1-asym peptide is also a target 
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residue for PRMT5. The identified arginine sites from hmSILAC still need to 





Figure 3.11 Validation of PRMT5 substrates. Recombinant GST tagged 
hnRNPA1, hnRNPH1, hnRNPK, SFPQ (1-57), SFPQ (298-707), KHDRBS1 
(81-443) and CNBP were incubated with PRMT5-MEP50 (A) and GST-





Figure 3.12 Validation of PRMT5 substrates by the in vitro radioactive 
methylation assay on synthetic peptides. Pre-methylated peptides (sym or 















3.4 PRMT5 SUBSTRATE SPECIFICITY  
3.4.1 PRMT5 targets Arg25 and Arg27 in CNBP 
Cellular nucleic acid binding protein (CNBP) is a RNA- and DNA-
binding protein that is involved in vertebrate craniofacial development 
(Calcaterra et al. 2010). CNBP was reported to contain asymmetrically and 
symmetrically dimethylated arginines and to be a substrate for PRMT1 (Wei 
et al. 2014). Arginine methylation of CNBP has been implicated in modulating 
its RNA binding capabilities (Wei et al. 2014). The CNBP contains one 
RGG/RG motif with four arginine residues (Arg25, Arg27, Arg32 and Arg34), 
and seven zinc fingers. All these four arginine residues on CNBP were 
identified in PRMT5 hmSILAC (Table 3.3). In order to confirm the arginine 
methylation sites for both PRMT5 and PRMT1, the four arginine residues 
were mutated to lysines and the mutant CNBP proteins were purified (Figure 
3.13A). The methyltransferase assays were conducted on these mutant CNBP 
proteins, using recombinant PRMT5-MEP50 and PRMT1. Compared to wild 
type, the methylation activity of PRMT5 on CNBP-R25K and -R27K was 
attenuated, but not on CNBP-R32K and -R34K. When mutated to lysine, both 
Arg25 and Arg27 abolished the methylation signal, which indicates that 
PRMT5 methylates Arg25 and Arg27 (Figure 3.13B). Surprisingly, when both 
Arg32 and Arg34 were mutated, the methylation signal was also slightly 
attenuated. We suspect that this double mutation may affect the PRMT5 
methylation on Arg25 and Arg27, or the binding of PRMT5 to the substrate. 
Nonetheless, these results suggest that PRMT5 prefers to target Arg25 and 







Figure 3.13 PRMT5-MEP50 and PRMT1 substrate specificity on CNBP. (A) 
Mutagenesis studies of the CNBP RGG/RG motif by mutating the arginine to 
lysine on Arg25, Arg27, Arg32 and Arg34. The RGG/RG motif is magenta 
and the zinc finger is cyan. In vitro radioactive methylation assays of PRMT5-
MEP50 (B) and GST-PRMT1 (C) on arginine mutant CNBP proteins. 
Arginine mutant CNBP proteins were recombinantly expressed with an N-
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terminal GST tag and purified on a glutathione Sepharose column. 200 nM of 
PRMT5-MEP50 or PRMT1 were incubated with 5 µM of CNBP and 14C-
SAM at 30 ˚C for 2 h.  
 
We next wanted to understand why Arg32 and Arg34 are not ideal 
methylation sites for PRMT5. We suspected that Ser31 blocked the 
methylation of these two arginine sites.  To prove this hypothesis, we first 
attenuated the methylation of Arg25 and Arg27 by mutating Gly26 to alanine, 
which totally abolished the arginine methylation by PRMT5. Next we mutated 
Ser31 to glycine. This CNBP-G26A/S31G is actively methylated by PRMT5 
(Figure 3.14), suggesting that the arginine methylation of PRMT5 is amino 




Figure 3.14 Ser31 blocks the methylation of Arg32 and Arg34 by PRMT5. 
(A) Mutant CNBP proteins: CNBP-G26A and CNBP-G26A/S31G. (B) In 
vitro radioactive methylation assay of PRMT5 on CNBP-WT, -G26A and -
G26A/S31G proteins.  
 
On the contrary to methylation by PRMT5, arginine methylation by 
PRMT1 on these mutant CNBP proteins did not have obvious reduction in 
methylation signal (Figure 3.13C). Our results implicate that PRMT5 has 
higher substrate specificity than PRMT1. It has been shown that PRMT1 
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methylates substrates beyond the RGG paradigm (Wooderchak et al. 2008). 
Substrate specificity of C. elegans PRMT5 has been characterized on histone 
H4 peptide with mutations on positively charged residues, but not on the 
glycines before and after the H4R3 (Wang et al. 2013). Therefore, it is 
interesting to investigate the substrate selectivity of PRMT5 on non-histone 
proteins.  
 
3.4.2 Glycine before target arginine site is important for PRMT5 
methylation  
In order to further understand the substrate specificity of PRMT5, we 
mutated Arg27 to glycine on CNBP. In this case, only one arginine can be 
methylated by PRMT5, which was confirmed by observing half of the 
methylation signal, when compared with WT CNBP (Figure 3.15). Gly24 on 
CNPB was further mutated into different amino acids and subjected to in vitro 
methylation by PRMT5. As shown in Figure 3.15, when Gly24 was replaced 
by polar, hydrophobic, or charged amino acids, it strongly attenuated PRMT5 
methylation of Arg25. This implies that an arginine residing after any amino 






Figure 3.15 Substrate specificity of PRMT5 on G24 mutant CNBP proteins. 
(A) Arg27 on CNBP was first mutated to glycine. Gly24 was further mutated 
to different amino acids on the CNBP-R27G construct. (B) Mutant CNBP 
proteins were expressed with a GST tag, purified and subjected to in vitro 
radioactive methylation assays with PRMT5. (C) Quantification of the 






Figure 3.16 Hydrogen bond forms between Gly2 of histone H4 and Phe580 of 
PRMT5. Histone H4 peptide and Phe580 on PRMT5 are shown in stick 
representation. The PRMT5 SAM binding domain is shown in red, the β-
barrel domain in yellow, the TIM domain in light pink, the SAM analog 
A9145C in green, the H4 peptide in magenta, and MEP50 in cyan. 
 
The human PRMT5-MEP50 structure provides the molecular basis of 
PRMT5 substrate binding. As shown in Figure 3.16, Gly2 on the histone H4 
peptide is the residue before the target arginine site, of which the main-chain 
carbonyl group forms a hydrogen bond with the main-chain amino group of 
PRMT5 Phe580. Gly2 is in close proximity to Phe580, therefore the 
substitution of this glycine residue to any other amino acid will clash with 
Phe580 and hinder the formation of this hydrogen bond.  
 
3.4.3 Glycine after target arginine site is important for PRMT5 
methylation 
Mutagenesis studies were also conducted in the CNBP-R27G 
construct. As expected, most of Gly26 mutant CNBP proteins were poor 
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substrates for PRMT5, except G26Y and G26K (Figure 3.17). To understand 
this selectivity, we modeled a mutated Gly4 on the substrate H4 peptide and 
proposed the following mechanism. As shown in Figure 3.18B, the main-chain 
carbonyl group of Ser1 of H4 forms a hydrogen bond with the side-chain 
amino group of Gln309 of PRMT5. Mutating the Gly4 to lysine on H4 may 
lead to the translocation of Gln309 residue on PRMT5 and break this 
hydrogen bond interaction. However, the side chain of lysine at this place may 
form a potential hydrogen bond with main-chain carbonyl group of Tyr307 
(Figure 3.18C). The same situation may happen on a G4Y mutant, the side-
chain of which contains a hydroxyl group that can be involved in hydrogen 
bond formation.  Whereas, replacement of Gly4 with a hydrophobic residue on 






Figure 3.17 Substrate specificity of PRMT5 on Gly26 mutant CNBP proteins. 
(A) Gly26 was substituted to different amino acids in CNBP-R27G construct. 
(B) Mutant CNBP proteins were subjected to in vitro radioactive methylation 
assays with PRMT5. (C) Quantification of radioactive signals and 







Figure 3.18 Proposed model to illustrate the interaction between the GRK 
motif and PRMT5. (A) Overall structure of PRMT5-MEP50 complex (PDB: 
4GQB). (B) Hydrogen bond forms between the Ser1 of H4 and Gln309 of 
PRMT5. (C) Model of substitution Gly4 to lysine residue on the H4 peptide. 
The histone H4 peptide, Tyr307 and Gln309 on PRMT5 are shown in stick 
representation. The PRMT5 SAM binding domain is shown in red, the β-
barrel domain in yellow, the TIM domain in light pink, the SAM analog 
A9145C in green, the H4 peptide in magenta, and MEP50 in cyan.  
 
3.5 DISCUSSION  
3.5.1 PRMT5 targets many RGG/RG motif-containing proteins 
In this study, we aimed to identify novel substrates and investigate the 
substrate specificity of PRMT5. Using both hmSILAC and ProtoArray® 
microarray technology, we have discovered many novel PRMT5 substrates. In 
the hmSILAC dataset, we observed the dynamic changes of methylated 
arginine residues from many RGG/RG motif-containing proteins, such as 
hnRNPA1, hnRNPH1, hnRNPK, SFPQ, KHDRBS1 and CNBP. These six 
targets were all validated in vitro as PRMT5 substrates. Regarding the arginine 
sites identified in this experiment, it might not be precise to consider all of 
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them as PRMT5 methylation sites, because we could not distinguish between 
the asymmetrically and symmetrically dimethylated arginines in hmSILAC. 
Some identified arginine sites could be the indirect effects of other PRMTs in 
cells upon PRMT5 deletion. Thus, these identified arginine sites need to be 
further validated in the future.  
Our second approach was the ProtoArray® microarray system, which 
is the first description of the substrate profiling for protein arginine 
methyltransferase using a motif antibody sdme-RG. sdme-RG is a cocktail of 
several monoclonal antibodies against symmetrically dimethylated arginine 
residues with a glycine residue at +1 position. Unexpectedly, we found that 
this antibody has non-specific binding to some RGG/RG-rich proteins with 
very high signal, such as coilin and RSP10, although these proteins contain 
unmodified arginines. This led to the loss of several known PRMT5 substrates. 
However, we were still able to identify many RGG/RG-rich proteins after a 
rigorous statistical analysis, such as SERBP1, TRIP6, CNBP and KHDRBS2.  
Using one antibody to detect a particular PTM on all the proteins is 
always limited by the specificity of the antibody. Here, the idea of using 
mixed monoclonal antibodies greatly improves the sensitivity of florescence-
based detection method. Motif antibody sdme-RG seems to have non-specific 
binding on some RGG/RG motif-containing proteins of the microarray, 
although this situation was not found on the Western blot analysis. 
Development of a novel antibody specific for the symmetrically dimethylated 
arginine can increase the number of hits and also promote this technique to 




3.5.2 Substrate specificity of PRMT5 
More than 1000 human proteins contain the RGG/RG motifs 
(Thandapani et al. 2013). In the case of both PRMT5 and PRMT1, we have 
predicted differential substrate specificities. Indeed, methylation assays on 
arginine mutant CNBP proteins indicate that PRMT5 is more restrictive in 
terms of substrate specificity than PRMT1. Moreover, the substrate specificity 
of PRMT5 on Gly24 and Gly26 mutant CNBP proteins indicates the glycine 
residue before or after the target arginine residue is critically important for 
arginine methylation. However, it is interesting to find that the substitution of 
Gly26 to tyrosine or lysine allows PRMT5 methylation. Therefore, PRMT5 
preferentially methylates arginines in GRG, GRY and GRK motifs. These 
findings can provide the amino acid sequence based prediction of the putative 
arginine sites for PRMT5 methylation.   
One example is the RG motif-containing protein eukaryotic translation 
initiation factor (eIF4E) (RG motif sequence: 107-
PAR(109)GR(111)GR(113)HP-115), a substrate for both PRMT1 and PRMT5. 
Mutagenesis studies have been performed on Arg109, Arg111 and Arg113 to 
characterize the arginine methylation by PRMT5 and PRMT1. On the eIF4E 
substrate, PRMT5 specifically methylates Arg111 and Arg113, while PRMT1 
methylates Arg109 (Zheng et al. 2013). Both Arg111 and Arg113 have a 
preceding glycine residue, which is consistent with our findings. One histidine 
follows after the Arg113, which suggests GRH could be another good 




3.5.3 Functional implications of arginine methylation by PRMT5 
The RGG/RG motif has been shown to be involved in mediating 
nucleic acid binding and protein-protein interactions, and to regulate cellular 
localization (Thandapani et al. 2013). Compelling evidence suggests that 
arginine methylation is a common mechanism regulating RGG/RG motif 
function. First, arginine methylation may affect the nucleic acid interactions of 
RNA binding proteins. Arginine methylation will not change the positive 
charge of the amino acid, but will remove the hydrogen bond donors and 
change the shape of arginine side chain. Arginine residues in protein-DNA 
complexes can make the hydrogen bond interactions with the backbone 
phosphate groups and with thymine, adenine, and guanine bases (Luscombe et 
al. 2001; Bedford & Clarke 2009). Several studies have reported that arginine 
methylation regulates RNA or DNA binding, such as in the case of SFPQ 
(Snijders et al. 2015). Second, arginine methylation may antagonize other 
PTMs, such as phosphorylation and citrullination. For example, arginine 
methylation of hnRNPK by PRMT1 inhibits the Ser302 phosphorylation by 
PKC kinase (Yang et al. 2014). Arginine methylation of SFPQ by PRMT1 is 
antagonized by citrullination (Snijders et al. 2015). Third, arginine 
methylation may regulate cellular localization of RNA binding proteins. 
Inhibiting the methylation using Adox on HeLa cells or deleting PRMT1 in 
embryonic stem cells led to the cytoplasmic accumulation of KHDRBS1 
(Bedford 2003). Fourth, arginine methylation could regulate protein-protein 
interaction. For example, symmetric arginine dimethylation of Sm proteins by 
PRMT5 is critical for their binding to SMN complex (Brahms et al. 2001). 
	  	  
74	  	  
SFPQ, hnRNPK and KHDRBS1 were only studied for asymmetric 
dimethylation by PRMT1. In case where both symmetric and asymmetric 
arginine dimethylations exist on the same protein, these two types of 
methylated arginines may contribute to distinct biological functions. It will be 
interesting to investigate whether the PRMT5-mediated symmetric arginine 
dimethylation on these proteins will have the same or different effects to 
PRMT1-mediated asymmetric dimethylation.   
 
3.5.4 Comparison of two different approaches: hmSILAC and 
ProtoArray® microarray  
Comparing the hmSILAC and ProtoArray® microarray techniques, it 
is clear that they have their own advantages and disadvantages in different 
aspects. First, SILAC is an accurate, quantitative and robust technique that has 
been widely used in biological research. hmSILAC has the great advantage of 
detecting the new generated methyl marks. By deleting PRMT5 in NPCs, we 
have detected the dynamic changes of specific methylated arginine residues 
caused by the defect of this specific methyltransferase in cells. Unlike SILAC, 
ProtoArray® microarray could not provide the information of specific 
methylated residues on target proteins. Second, the hits identified by 
hmSILAC were mainly abundant proteins in cells. For low expression 
proteins, we might not be able to identify them as high confidence hits. The 
advantage of ProtoArray® microarray over hmSILAC is that every protein is 
spotted on the array at a similar concentration, and the selection criteria are 
based on the positive signals in relation to the distribution of all protein 
signals. Third, the protein microarray only detects direct methylations whereas 
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SILAC may include secondary methylations from other enzymes. Forth, 
unlike the requirement of expertise in SILAC analysis, protein microarray is 
convenient, fast and easy technique for most researchers. Due to the above 
differences, a combination of these two techniques will complement each 
other for the target identification of specific protein methyltransferases.  
 
3.5.5 Demethylase  
With an increasing number of the identified methylated arginines, it is 
surprising that the demethylation events for these arginine methylated proteins 
are largely unknown. So far, histone demethylases LSD and JMJC are two 
conserved families for histone and some non-histone demethylation. Most of 
these demethylases were found to be specific for lysine residues on histones. 
Jumonji domain-containing 6 protein (JMJD6) is the only identified 
demethylase that can demethylate histone arginine residues H3R2 and H4R3 
(Chang et al. 2007), although this finding has been questioned (Webby et al. 
2009; Unoki et al. 2013).  Dynamic regulation of arginine methylation and 
demethylation events on non-histone proteins is particular interesting area for 





CHAPTER 4  
BIOCHEMICAL STUDIES OF THE PRDM9 AND PRDM15 
PR DOMAINS 	  
4.1 THE PRDM9 PR DOMAIN METHYLATES HISTONE H2A, 
H2B, H3 AND H4 
PRDM9 was known to tri-methylate histone H3K4 (Hayashi et al. 
2005). In order to study the substrate specificity and catalytic activity of other 
PRDM family members, PRDM9 was chosen as an ideal positive control. At 
that time, no detailed biochemical characterization of the PRDM9 PR domain 
has been performed. A construct that harbors the mouse PRDM9 PR domain 
amino acids 192-377, was soluble when expressed in E. coli.  Thus 
recombinant PRDM9 (192-377) was used in this study (Figure 4.1). The in 
vitro methyltransferase assay was performed by incubating the reaction of 2.5 
µM of PRDM9, 10 µM of histone protein and 14C-SAM at 30 ˚C for 2 h. 
Unexpectedly, PRDM9 is able to methylate histone H2A, H2B, H3 and H4 
(Figure 4.2A). With the use of 100 nM PRDM9, only H3 is strongly 
methylated (Figure 4.2B). This means that H3 is still the most prevalent 
substrate for PRDM9. The PRDM9 PR domain is enzymatically highly active 






Figure 4.1 Recombinant mouse PRDM9 protein. (A) Graphic illustration of 
full length mPRDM9 and truncated mPRDM9 (192-377). The PR domain is 
red, KRAB is light blue, the zinc knuckle is magenta and the zinc finger is 
blue. This figure was drawn using DOG 1.0 (Ren et al. 2009). (B) Purified 
mPRDM9 (192-377) was analyzed for purity by SDS-PAGE. Molecular 







Figure 4.2 Recombinant mPRDM9 (192-377) shows a broad substrate 
specificity on histones. In vitro methylation assay of mPRDM9 (192-377) on 
histones. 2.5 µM (A) or 100 nM (B) of recombinant PRDM9 protein was 
incubated with 14C-SAM and 10 µM of H2A, H2B, H3 and H4 at 30 ˚C for 2 
h. Incorporation of the radioactive methyl group from the 14C-SAM donor was 





4.2 IDENTIFICATION OF METHYLATED SITES ON HISTONE 
H3 AND H4 BY PRDM9 
Next, in order to identify methylation sites on histone H3, 400 nM 
PRDM9 was used to methylate H3K4me1, H3K4me2, H3K4me3, H3K9me3 
and H3K27me3 peptides. PRDM9 can methylate all of these peptides, with 
exception of H3K4me3, which indicates that at low levels of enzyme, H3K4 is 
the optimal target site for PRDM9 (Figure 4.3). We collaborated with the lab 
of J. Hill at ETC to characterize the lysine methylation of PRDM9 and its 
binding affinity to substrates and the cofactor, using mass spectrometry and 
isothermal titration calorimetry. In addition, methylation reactions containing 
very limited amount of PRDM9, H3 peptide (1-21) and SAM, were analyzed 
by MALDI-TOF/TOF MS. MALDI-TOF/TOF MS analysis proves that H3K4 
was mono-, di- and tri-methylated by PRDM9 (Koh-Stenta et al. 2014). Under 
saturating condition of PRDM9 and SAM, additional sites on Lys9 and Lys18 
were methylated by PRDM9 (Koh-Stenta et al. 2014). On the histone H4 
peptide (1-36), only monomethylated product was formed, and by using ESI 
ETD MS/MS this monomethylated site was identified as H4K20 (Koh-Stenta 






Figure 4.3 Recombinant mPRDM9 (192-377) methylates H3K4. 400 nM 
mPRDM9 (192-377) was incubated with H3K4me1, H3K4me2, H3K4me3, 




4.3 BINDING AFFINITY OF PRDM9 TO HISTONE PEPTIDE H3 
(1-21) AND COFACTOR SAM 
Canonical SET domains tend to bind to their peptide substrates with 
dissociation constants (Kd) in the µM range. We analyzed the binding of 
mPRDM9 (192-377) to unmodified H3 peptide (residues 1-21) and SAM by 
isothermal titration calorimetry (Figure 4.4A, B). Our ITC assay shows that 
mPRDM9 (192-377) interacts with SAM with Kds of ~ 17.6 and 42.6 µM, 
respectively (Koh-Stenta et al. 2014). We also measured the binding between 
SAH and PRDM9/H3 peptide complex. As compared to PRDM9 alone, highly 
negative ΔG values were observed for the PRDM9/H3-peptide complex bound 
to SAH (Figure 4.4C). Substrate binding seems to favor the interaction of 
PRDM9 with cofactor SAH. The crystal structure of mPRDM9 (198-368) 
indicates that the post-SET domain is disordered in the absence of substrate 
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Figure 4.4 Isothermal titration calorimetry (ITC) analysis of mPRDM9 (192-
377) with H3 peptide and SAM (Koh-Stenta et al. 2014). ITC measurement of 
the interaction between H3 peptide (1-21) (A) or SAM (B) and mPRDM9 
(192-377). (C) ITC measurement of the interaction between PRDM9/H3 
peptide (1-21) complex with SAH.  
 
 
4.4 IDENTIFICATION OF NON-HISTONE SUBSTRATES FOR 
PRDM9 BY PROTEIN MICROARRAY 
Many SET domain containing proteins have been known to target non-
histone substrates (Herz et al. 2013). Since the PRDM9 PR domain shows 
more extensive substrate specificity than previously described, we decided to 
identify potential non-histone substrates. Human ProtoArray® platform has 
been previously used to profile substrates for PKMTs using fluorescence- and 
radioactive-based detection approaches (Levy et al. 2011). Fluorescence-based 
detection approach is highly dependent on the antibody specificity (Levy et al. 
2011). Polyclonal anti-methylated lysine antibody ab23366 (Abcam) detects 
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mono- and di-methylated lysine, and may also react with tri-methylated lysine. 
Although it did not cross-react with unmethylated lysines, it was found to fail 
to detect all the methylated peptides (Levy et al. 2011). Therefore, it is 
important to keep in mind that the targets we identified in this experiment 
maybe incomplete due to the antibody sensitivity and specificity. 	  
 
 
Figure 4.5 Human and mouse PRDM9 PR domains are highly conserved. (A) 
Graphic illustration of hPRDM9 (195-385). The PR domain is red, KRAB is 
yellow, the zinc knuckle is blue and the zinc finger is cyan. This figure was 
drawn using DOG 1.0 (Ren et al. 2009). (B) Sequence alignment of human 
and mouse zinc knuckles and PRDM9 PR domains. The alignment was 
performed using Clustal Omega.  (C) Purified recombinant His-hPRDM9 







Figure 4.6 hPRDM9 (195-385) methylates non-histone substrates. (A) In vitro 
methylation of hPRDM9 (195-385) on the human protein microarray. 
Antibody ab23366 clearly recognized the methylated but not the unmodified 
H3.  (B) Scanned images of one negative control and two PRDM9 protein 
microarrays. Protein microarrays were incubated in the methylation reaction 
containing 1 µM of hPRDM9 (195-385) or buffer (as negative control) with 
200 µM of SAM at 30 ˚C for 2 h. (C) Venn diagram shows the overlap of hits 
from control and PRDM9 arrays. Hits were selected based on Z-factor > 0.35, 
Z-score > 2 and spot CV < 0.5. The Venn diagram was generated by Venny 
2.0.   
 
Human and mouse PRDM9 PR domains share a 90% amino acid 
sequence identity (Figure 4.5). In order to identify the non-histone substrates 
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for PRDM9, recombinant human PRDM9 (195-385) was purified from E. coli 
and subjected to the methylation assay on the human protein microarray with 
antibody ab23366 (Figure 4.6A, B). Two arrays were performed for PRDM9 
and one array for the negative control without PRDM9. Hits for the arrays 
were selected based on Z-Factor > 0.35, Z-Score > 2 and spot CV < 0.5. Here, 
a lower Z-Score cut-off was used because we identified less positive hits in the 
PRDM9 arrays, when compared to PRMT5. By overlapping the hits between 
two PRDM9 arrays and one control array, we identified four candidate hits on 
two PRDM9 arrays (Figure 4.6C). Next, among these four hits, only the signal 
ratios of uracil-DNA glycosylase (UNG) and enhancer of mRNA decapping 3 
homolog (EDC3) are higher than 1.5, although they all have high Z-Scores in 
PRDM9 arrays (Table 4.1-4.2, Figure 4.7). Additional, there are 33 proteins 
which passed through the above three statistical thresholds among all three 
arrays. However, the signal ratios of these proteins are all below 1.5. Taken 
together, we identified UNG and EDC3 as novel non-histone substrates of 
PRDM9 PR domain in vitro.  
 
Table 4.1 Z-Scores of four putative hits identified on the PRDM9 protein 
microarray 
 







NM_080911.1 UNG 0.65548 4.16154 4.03939 
NM_025083.2 EDC3 -0.08988 2.82634 2.15768 
NM_199139.1 XAF1 1.78645 2.54609 2.90679 












Table 4.2 Signals and signal ratios of four putative hits identified from the 
PRDM9 protein microarray 
 
















NM_080911.1 UNG 1522 5338.5 8208 3.51 5.39 4.45 
NM_025083.2 EDC3 36.5 3680.5 4523 100.84 123.92 112.38 
NM_199139.1 XAF1 3776 3332.5 5990 0.88 1.59 1.23 










EDC3 was recombinantly expressed as an N-terminal GST-tagged 
fusion protein in E. coli, purified and tested in the in vitro radioactive 
methyltransferase assay. As shown in Figure 4.8, EDC3 can only be 
methylated by the wild type but not the catalytic mutant PRDM9. EDC3 is an 
enhancer of mRNA decapping that belongs to the Lsm16 family. It is still 






Figure 4.8 hPRDM9 (195-385) can methylate EDC3. hPRDM9 (195-385) 
was incubated with GST-hEDC3 in the in vitro radioactive methylation.   
 
 
4.5 ENZYMATIC ACTIVITY OF THE PRDM15 PR DOMAIN ON 
HISTONES 
PRDM15 is another PRDM family member about which very little is 
known. The PR domain of PRDM15 is flanked by a zinc knuckle and 17 zinc 
finger domains. The enzymatic activity of PRDM15 has not been reported yet. 
Thus, it is still unknown whether PRDM15 PR domain is catalytically active 
on either histone or non-histone proteins. Full length mouse PRDM15 is 
insoluble in E. coli and insect cells. After extensive testing of multiple 
constructs (Table 4.3), several constructs were found to be soluble in E. coli. 
Recombinant mPRDM15 (29-174) was purified and incubated with histones 
for the methylation assay (Figure 4.9). However, no methylation signal was 
detected. Thermal shift assay has been performed on mPRDM15 (29-174), but 
there was not significant temperature shift with the addition of SAM. To know 
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whether the zinc knuckle preceding the PR domain is necessary, hPRDM15 
(302-537) containing this additional zinc knuckle, was recombinantly purified 
and subjected to methylation assay with histones (Figure 4.9). However, 
hPRDM15 (302-537) could not catalyze methylation on histone substrates. We 
also tested other soluble constructs in Table 4.3, but none of them were found 
to be catalytically active on histones. We thus conclude that the PRDM15 PR 
domain alone is catalytically inactive on histone substrates, but we cannot 
exclude that the full length protein has catalytic activity.   	  	  
Table 4.3 Table of constructs used for recombinant expression of PRDM15 
proteins 
 
Species Constructs (with His-tag) 
Solubility in 
 E. coli Domains 
Human PRDM15 (329-540) Soluble PR domain 
Human PRDM15 (335-537) Soluble PR domain 
Human PRDM15 (335-540) Soluble PR domain 
Human PRDM15 (302-537) Soluble Zinc knuckle and PR domain 
Human PRDM15 (307-537) Soluble Zinc knuckle and PR domain 
Human PRDM15 (302-589) Insoluble Zinc knuckle, PR and first zinc finger domain 
Human PRDM15 (302-601) Slightly soluble Zinc knuckle, PR and first zinc finger domain 
Human PRDM15 (302-619) Slightly soluble Zinc knuckle, PR and first zinc finger domain 
Mouse PRDM15 (29-174) Soluble PR domain 
Mouse PRDM15 (35-170) Soluble PR domain 
Mouse PRDM15 (7-165) Soluble Zinc knuckle and PR domain 







Figure 4.9 Purified recombinant PRDM15 PR domains. (A) Graphic 
illustration of mPRDM15 (29-174) and hPRDM15 (302-537). The PR domain 
is red, the zinc knuckle is blue and the zinc finger is cyan. This figure was 
drawn using DOG 1.0 (Ren et al. 2009). (B) Purified recombinant mPRDM15 
(29-174) and hPRDM15 (302-537) were analyzed for purity by SDS-PAGE.  
 
4.6 ENZYMATIC ACTIVITY OF THE PRDM15 PR DOMAIN ON 
NON-HISTONE PROTEINS 
Next, we performed the methylation assay of recombinant hPRDM15 
(302-537) on the ProtoArray® microarray to understand whether PRDM15 
targets non-histone substrates (Figure 4.10). Data were analyzed using the 
same parameters as PRDM9. Only one hit (C1orf77) was identified in the 
overlap region of PRDM15 arrays. However, the signal ratio of C1orf77 is 
below 1.5, which is unlikely to be PRDM15 substrate (Table 4.4). We also 






Figure 4.10 Substrate profiling of hPRDM15 (302-537) using the protein 
microarray system. (A) In vitro methylation assay of hPRDM15 (302-537) on 
the human protein microarray. Images of one negative control and two 
PRDM15 protein microarrays. Protein microarrays were incubated in the 
methylation reaction containing 1 µM of PRDM15 or buffer (as negative 
control) with 200 µM of SAM at 30 ˚C for 2 h. (B) Venn diagram shows the 
overlap between the hits of control and PRDM15 arrays. Hits were selected 
based on Z-factor > 0.35, Z-score > 2 and spot CV < 0.5. The Venn diagram 
was generated by Venny 2.0.  (C) Magnified images of C1orf77 from arrays.  
 

















BC002733.2 C1orf77 3308.5 4835.5 4576.5 1.46 1.38 1.42 
 
4.7 CRYSTALLIZATION AND STRUCTURAL DETERMINATION 
OF THE MOUSE PRDM15 PR DOMAIN 
4.7.1 Crystallization trials of the PRDM15 PR domain     
Crystal structure of the PRDM15 PR domain is not available in PDB 
database. Thus, purified mPRDM15 (29-174) was concentrated to 15 mg/ml 
and subjected to crystallization screening.  Crystallization trials were set up as 
hanging drops with 1:1 (v/v) mixture of protein solution and precipitant at 24 
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°C. PRDM15 was crystalized in some conditions containing 20% v/v PEG 550 
MME and 10% w/v PEG 20K from Morpheus crystallization screen 
(Molecular Dimensions). Crystals were observed after 48 h as diamond and 
rod cluster (Figure 4.11). Single rods from the clusters were flash frozen in 
liquid nitrogen for data collection.  
 
 
Figure 4.11 Crystals of mPRDM15 (29-174). The crystal conditions are 
indicated below each image. The scale bar indicates the size. 
 
4.7.2 X-ray data collection of mPRDM15 (29-174) crystals 
Crystals grown in 0.1 M Tris-HCl, pH 8.5, 20% v/v PEG 550 MME, 
10% w/v PEG 20000 were subjected to data collection at the National 
Synchrotron Radiation Research Center, Taiwan (NSRRC).  
 
4.7.3 Structure determination, model building and refinement 
The crystal of mPRDM15 (29-174) belongs to the space group P1 with 
unit cell dimensions a=62.1 Å, b=70.7 Å, c=74.8 Å, α=114.1 o, β=91.4 o, 
γ=115.4 o. The asymmetric unit of PRDM15 crystals contains six molecules 
(Figure 4.12). Crystallographic data were indexed, integrated and scaled using 
HKL2000. PRDM10 (PDB code: 3IHX) was chose as the search model as it 
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shares 40% sequence identity with mPRDM15 (29-174). Molecular 
replacement was performed with Phaser in the PHENIX software suite. 
Automated model building and refinement were conducted with AutoBuild 
from PHENIX and manual building was performed using the graphics 
program COOT.  The structure was subjected to several rounds of refinement 
in PHENIX to an overall Rwork of 0.194 of and Rfree of 0.246. All residues are 




































Table 4.5 Data collection, processing and refinement statistics for mPRDM15 
(29-174) 
 
Data collection statistics 
Synchrotron Taiwan NSRRC 
Beamline BL13B1 
Space group P1 
Molecules, AU 6 
Cell dimensions   
a, b, c (Å) 62.1, 70.7, 74.8 
α, β, γ (°)  114.1, 91.4, 115.4 
Wavelength  (Å) 0.99997 
Resolution  (Å) 30-2.00 
Rmerge (%) a 3.7 (30.6) 
Mean I/σ(I) a 11.3 (4.3) 
Completeness (%) a 95.6 (86.7) 
Redundancy a 2.0 (1.7) 
Refinement statistics 
Resolution (Å) 25.7-2.00 
Number of reflections 57830 
Rwork /Rfree (%) 19.4/24.6 
Number of atoms   
Protein 6913 
Water 565 
Average B-factors (Å) 24.9 
R.M.S.Deviations   
Bond lengths (Å) 0.011 
Bond angles (°) 1.307 
Ramachandran plot   
Favored (%) 98.47 
Outlier (%) 0 
 
a Values in parenthesis are the highest-resolution shell. AU, asymmetric unit.  
b Rmerge= Ʃi Ʃh(|Ij,h -<Ih>|) / ƩjƩh(<Ih>), where h are unique reflections 
indices, i, j, h are intensities of symmetry related reflections and <Ih> is the 
mean intensity. 
c Rwork and d Rfree are defined by R= Ʃ hkl||Fobs|- |Fcalc|| / Ʃ hkl |Fobs|, where 
h, k, l are the indices of the reflections (used in refinement for Rwork; 5 %, not 
used in refinement, for Rfree), Fobs and Fcalc are the structure factors, deduced 
from measured intensities and calculated from the model, respectively. 
 
 
4.7.4 Structure of PRDM15 PR domain  
We solved the crystal structure of the PR domain from mPRDM15 
(29-174) at resolution 2.0 Å (Figure 4.12A). The crystal of mPRDM15 (29-
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174) contains six molecules on one asymmetric unit (Figure 4.12B). Two 
symmetry molecules of mPRDM15 (29-174) interact with each other via the 
long N-terminal tails. However, mPRDM15 (29-174) exists as monomer in 
solution (data not shown).  
 
 
Figure 4.12 Crystal structure of mPRDM15 (29-174). (A) Structure of 
mPRDM15 (29-174). (B) Crystal packing of mPRDM15 (29-174) in one 
asymmetric unit. (C) Two symmetry molecules in crystal packing.  
 
The structure of mPRDM15 (29-174) adopts a typical SET fold with 
several β-strands and intervening loops. Superimposition of PRDM15 to 
PRDM9 structure shows that the structural differences are the pre-SET and 
post-SET regions (Figure 4.13). Due to the lack of zinc knuckle, the pre-SET 
region of PRDM15 is disordered. The post-SET domain usually forms part of 
the enzymatic domain upon the substrate binding. The post-SET domain of 
PRDM15 forms an α-helix like PRDM9, but is pointed away from the 
catalytic site as compared to PRDM9 (Figure 4.13) (Wu et al. 2013). In the 
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PRDM9 structure, this post-SET domain is stabilized by the N-terminal zinc 
knuckle domain. Hence, the different position of post-SET domain in the 
PRDM15 structure might be due to the lack of this zinc knuckle domain in this 
construct.  
 
Figure 4.13 Superimposition of mPRDM15 (29-174) to PRDM9 structure 
(PDB: 4C1Q). Pre-SET domains and Post-SET domains of two structures are 
highlighted by blue and black dashed line box.  
 
 
To understand why PRDM15 PR domain is catalytically inactive on 
histones, we performed amino acid sequence alignment on mouse PRDM9 and 
PRDM15 PR domains (Figure 4.14). In the active site of PRDM9, three 
tyrosine residues (Tyr276, Tyr341 and Tyr357, the corresponding amino acids 
on PRDM15 are Phe78, Phe142 and Tyr158) form a hydrophobic channel 
around the ε-amino group of target lysine residue (Figure 4.15A) (Wu et al. 
2013). These three tyrosine residues surround the substrate H3K4me2 ε-amino 
group and are important for PRDM9 catalytic activity. Mutating any of these 
tyrosine residues to phenylalanine completely abolished its methyltransferase 
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activity (Wu et al. 2013). Tyr276 and Tyr341 residues from PRDM9 are 
replaced by phenylalanine on PRDM15 structure (Figure 4.15A). Tyr341 
residue from PRDM9 helps in coordinating a water molecule in the active site 
by its hydroxyl group, which is not possible for phenylalanine. The Tyr357 
residue from the post-SET region of PRDM9 is conserved on many other 
PRDM members, which has been proposed to be involved in catalysis. 
However, this tyrosine corresponding to Tyr158 on PRDM15 is not in 
proximity to cofactor SAH (Figure 4.15A).  Tyr291 from PRDM9 forms 
another important hydrogen bond with cofactor SAH (Figure 4.15B).  
However, the corresponding tyrosine on PRDM15 is replaced by Phe92 and 




Figure 4.14 Sequence alignment of mouse PRDM15 and PRDM9 PR 
domains. The alignment was performed using Clustal Omega. The important 






Figure 4.15 The critical tyrosine residues for PRDM9 methylation are not 
conserved on mPRDM15. (A) Tyr276, Tyr341 and Tyr357 are important for 
PRDM9 methylation. The corresponding residues on PRDM15 are Phe78, 
Phe142, and Tyr158. (B) Tyr291 from the PRDM9 structure forms a hydrogen 
bond with SAH with a bond length of 2.8 Å, which is missing on PRDM15 
structure. Phe92 in the PRDM15 structure locates in a different position. 
PRDM9 is magenta (PDB: 4C1Q; (Wu et al. 2013)), mPRDM15 (29-174) is 
green, H3K4me2 is grey, and SAH is yellow. The water molecule in PRDM9 
structure is shown as magenta sphere. 
 
Asn320 another important residue involved in PRDM9-SAH binding 
(Wu et al. 2013), is not conserved in PRDM15 (Figure 4.14). In the PRDM9 
structure, Asn320 forms an important hydrogen bond with SAH via its side 
chain (Figure 4.16A). However, the corresponding residue on PRDM15 
structure is Arg121. That results in the loss of the hydrogen bond with SAH in 
PRDM15. To further address the importance of Asn320, we mutated Asn320 
to arginine (N320R) residue on PRDM9. As seen in Figure 4.16B, this single 
mutation abolished the activity of PRDM9 on histones. These data suggest that 






Figure 4.16 Arg121 residue in the SAM binding pocket of mPRDM15. (A) 
Asn320 forms a hydrogen bond with SAH in the PRDM9 structure with a 
bond length of 3.0 Å, which is replaced by arginine in the PRDM15 structure. 
PRDM9 is magenta (PDB: 4C1Q; (Wu et al. 2013)), mPRDM15 (29-174) is 
green, and SAH is yellow. (B) N320R abolishes the catalytic activity of 
PRDM9. The in vitro methylation assay was performed using 400 nM of WT 
and mutant PRDM9 and 10 µM of histone proteins. 
 
 
4.8 DISCUSSION  
4.8.1 PRDM9 activity towards histones  
In this study, we investigated the enzymatic activity of the PRDM9 PR 
domain, which is structurally similar to the SET domain. We demonstrated 
that the PRDM9 PR domain can actively methylate histones H2A, H2B, H3 
and H4 in vitro. However, histone H3 is the most prevalent substrate for 
PRDM9 among four core histones. Interestingly, PRDM9 not only tri-
methylates H3K4, but also catalyzes mono- and di-methylation, which is 
distinct to the earlier characterization of PRDM9 enzymatic activity. With 
saturating SAM and enzyme, lysine 9 and 18 on histone H3 can be further 
methylated. Notably, histone H4K20 can be monomethylated under non-
saturating conditions. It is still unknown whether H4K20 can be methylated by 
PRDM9 in vivo. Most recently, PRDM9 was reported to efficiently mono-, di-
, and tri-methylate H3K36 in vitro and in HEK293 cells (Eram et al. 2014). In 
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our study, due to the short length of the H3 peptide (1-21), we did not identify 
lysine 36 as a PRDM9 target site.   
Wu et al. and his colleagues reported that the first zinc finger can auto-
inhibit PRDM9 catalytic activity. In the context of full length PRDM9, we 
question whether other C-terminal zinc fingers also take a part in 
autoinhibition. Binding of these zinc fingers to DNA also creates the direct 
locus contact between PR domain and histone substrates. The enzymatic 
activity of the PRDM9 PR domain might be also different to that observed in 
vitro. Canonical SET domains from lysine methyltransferases require other 
adjacent domains to recruit substrates or other binding partners in order to 
execute their enzymatic activities. The KRAB domain is commonly present in 
zinc-finger transcription factors and acts as transcriptional repressor domain 
(Urrutia 2003). Whether the N-terminal KRAB domain can form part of 
catalytic domain of PRDM9 and regulate its substrate binding remains to be 
established.  
PRDM9 is a key determinant of meiotic recombination hotspots in 
human and mouse, and lack of Prdm9 in mice led to the reduction of 
H3K4me3 and the impairment of double strand break repair (Hayashi et al. 
2005; Baudat et al. 2010). The H3K4me3 mark was found to be enriched on 
recombination initiation sites in mouse and yeast (Buard et al. 2009; Borde et 
al. 2009). The H4K20me1 mark is associated with transcriptional activation. 
Although the histone marks methylated by PRDM9 in vitro may not display 
the same modifications in cells, it would still be interesting to know whether 
the H4K20me1 mark plays a role in the epigenetic control of meiotic 




4.8.2 PRDM9 methylates non-histone substrates 
SET domain-containing proteins were initially characterized to target 
histone substrates, while recently several non-histone substrates have been 
described. Therefore, not surprisingly, also PRDM9 was found to methylate at 
least two non-histone targets: UNG and EDC3, which were identified using 
the ProtoArray® microarray technology. Neither of them had been known to 
harbor methylated lysine residues. We further validated EDC3 methylation by 
PRDM9 in vitro. Next, the priority is to find out whether UNG and EDC3 
carry the methylated lysine residues in vivo. EDC3 is the activator of 
Dcp1:Dcp2 decapping complex and assembly of processing bodies (P-bodies), 
(Fenger-Grøn et al. 2005; Decker et al. 2007). UNG is the major uracil-DNA 
glycosylase that catalyzes the removal of uracil from DNA and initiates the 
base excision repair (BER) (Nilsen et al. 2000). Future studies are needed to 
unravel the effects and physiological relevance of lysine methylation on EDC3 
and UNG.  
 
4.8.3 PRDM15 PR domain is catalytic inactive 
In the contrast to the PRDM9 PR domain, the PRDM15 PR domain is 
catalytically inactive towards histones and non-histone proteins. The zinc 
knuckle preceding the PR domain does not favor the enzymatic activity. We 
have determined the crystal structure of the PRDM15 PR domain. The crystal 
structure of the PRDM15 PR domain adopts a relative open conformation as 
compared to PRDM9. Two important tyrosine residues in the active site are 
substituted by phenylalanine residues on PRDM15. Moreover, Asn320 and 
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Tyr291, which form a hydrogen bond with cofactor SAH on PRDM9, are not 
conserved in the PRDM15 PR domain. Mutation of Asn320 to arginine in 
PRDM9 results in complete abrogation of the enzymatic activity. PRDM3 and 
PRDM16 are two reported H3K9 methyltransferases that maintain the 
integrity of mammalian heterochromatin (Pinheiro et al. 2012).  Surprisingly, 
both of them have the arginine residue instead of asparagine in the SAM 
binding site. It might be possible that additional residues on PRDM3 and 
PRDM16 may mediate the interaction with SAM. Elucidating the structure of 
the PRDM3 PR domain in complex with SAM will help to illustrate the 
molecular basis behind this difference. Thus, it is still difficult to predict the 
catalytic activity of the PR domains only based on the amino acid sequence 





CHAPTER 5  
DISCUSSION AND FUTURE RESEARCH 	  
5.1 DISCUSSION  
5.1.1 Dynamic changes of methylated arginines upon the deletion of 
PRMT5  
As the major type II arginine methyltransferase, PRMT5 was known to 
methylate both histones (H2A, H3 and H4) and many non-histone proteins, 
such as Sm proteins (Brahms et al. 2000), RSP10 (Ren et al. 2010) and E2F-1 
(Zheng et al. 2013). However, there was not, to date, a systematic 
characterization of PRMT5 targets. With the use of hmSILAC, the majority of 
the dynamic methylation of arginines was found to be down regulated upon 
PRMT5 deletion, especially the arginine residues in RGG/RG motifs. Most of 
these down-regulated methylation marks on arginines are likely to be at sites 
normally targeted by PRMT5. Interestingly, we also observed some up-
regulated arginine sites (Table A1). We speculate that upon PRMT5 deletion, 
PRMT1 may be able to increase the extent of its arginine methylations.  
This kind of interplay between the different types of arginine 
methylation has been studied on PRMT1 knockout and PRMT5 knockdown 
cells (Dhar et al. 2013). Loss of the PRMT1 in MEFs has been shown to 
dramatically increase the global level of monomethylation and symmetric 
dimethylation of arginines in cells using the type-specific antibodies (Dhar et 
al. 2013). Knockdown of PRMT5 on HeLa cells did not result in the large-
scale generations of monomethylated substrates, but only led to the increase of 
the monomethylation on SmB protein and asymmetric dimethylation on one 
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protein at 30 kDa (Dhar et al. 2013). This phenomenon for PRMT5 could be 
caused by the incompleteness of knockdown.  Our study showed that knockout 
PRMT5 on NPCs led to the large-scale loss of symmetric dimethylation of 
arginines in cells, and to the decrease of monomethylation on some proteins 
with the type-specific antibodies on Western blot analysis. The loss of 
symmetric arginine dimethylation does not seem to be compensated by the 
asymmetric arginine dimethylation in global level. Since some up-regulated 
arginine methylations were observed in our hmSILAC upon the loss of 
PRMT5, we suspect that the interplay between symmetric and asymmetric 
arginine dimethylation may only happen on specific proteins.  
Here, we also define the more specific motifs for PRMT5. By 
performing methylation on different arginine mutant CNBP proteins, PRMT5 
was shown to prefer to methylate Arg25 and Arg27 on CNBP and displays 
higher substrate specificity than PRMT1. To further understand whether 
PRMT5 can methylate arginines in other contexts, we mutated the glycine 
before and after the target arginine residue of CNBP. Surprisingly, a single 
mutation of the glycine residue before the target arginine residue of CNBP led 
to the abrogation of PRMT5 methylation. Replacement of the glycine residue 
after the target arginine to other residues also resulted in inhibition of arginine 
methylation, except when replaced by tyrosine or lysine. The tyrosine or 
lysine residue after the target arginine site still has 50-60% of PRMT5 
methylation signal as compared with GRG motif. Thus, other than GRG motif, 
PRMT5 also targets arginine nesting within GRY and GRK motifs. This study 
can provide the basis for prediction of target arginine sites for PRMT5 by 
examining the protein amino acid sequence databases.  
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Although substrate sequence is important for methylation, within the 
physiological setting, the methylations catalyzed by methyltransferases are 
more complicated than what are observed in vitro. The protein arginine 
methylation might be dynamic regulated by other types of PTMs, cellular 
localization of the substrate and enzyme, and other binding partners. Within 
CNBP, methylations of all four arginine residues were found to be down 
regulated in hmSILAC analysis, which indicates that methylation at those four 
sites could not be compensated by other PRMTs. The in vitro methylation 
assay suggests that the Arg25 and Arg27 can be strongly methylated by both 
PRMT5 and PRMT1, while the Arg32 and Arg34 can only be methylated by 
PRMT1. We could not explain the loss of dimethylation on Arg32 and Arg34 
within the PRMT5 deleted cells. Thus, it is possible that loss of PRMT5 
affects the PRMT1 methylation on these two sites via other indirect effects. 
Taken together, our hmSILAC data suggests that the loss of PRMT5 
results in the major decrease on the methylation of arginines within RGG/RG 
motifs, and also emphasizes the role of PRMT5 as the major type II enzyme. 
The dynamic interplay between different types of arginine methylation again 
suggests that some proteins can be competitively targeted by different 
methyltransferases in vivo. In addition, the in vitro evidences of PRMT5 
substrate specificity can provide the basic knowledge for further investigating 
the functional effects of arginine methylations in vivo.  
 
5.1.2 Potential functions of PRMT5 methylation on KHDRBS1 
Here, many RGG/RG-motif containing proteins were identified as 
PRMT5 targets, which provide us a good starting point for the functional 
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studies in future. Although both PRMT5 and PRMT1 target the RGG/RG-
motif containing proteins, study on CNBP revealed their differential substrate 
specificity. This raises the question whether the symmetric and asymmetric 
arginine dimethylation regulate the same or different functions on these 
substrates. For instance, KHDRBS1 is involved in many aspects of RNA 
metabolism, such as alternative splicing and polysomal recruitment of 
mRNAs. KHDRBS1 is predominantly nuclear and can shuttle to cytoplasm. 
Since inhibiting the protein methylation using Adox on HeLa cells induced the 
cytoplasmic accumulation of KHDRBS1, it is possible that the symmetric 
arginine methylation of KHDRBS1 by PRMT5 might also regulate the 
translocation of KHDRBS1. The translocation of KHDRBS1 could further 
affect its polysomal association, which is related to the translational 
machinery. In addition, the RGG/RG motifs of KHDRBS1 are in the vicinity 
of its proline-rich motif. The asymmetric dimethylation of arginine residues 
within these RGG/RG motifs have been shown to reduce the binding of the 
SH3 domains of p59fyn and phospholipase Cγ-1, but not the WW domain of 
FBP30 (Papers et al. 2000). We suspect that the symmetric arginine 
dimethylation will cooperate with asymmetric arginine dimethylation in 
selectively regulating the protein-protein interaction. The regulation of 
arginine methylation of KHDRBS1 on alternative splicing is unknown.  
KHDRBS1 directly binds to SMN2 exon-7 to promote the exon skipping 
(Pedrotti et al. 2010). KHDRBS1 physically interact with hnRNPA1 via its C-
terminal region (aa 351-443), which contains the RGG/RG and proline-rich 
motifs. This interaction favors SMN2 alternative splicing. It is possible that the 
arginine methylation on RGG/RG motifs may regulate the interaction between 
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KHDRBS1 and hnRNPA1, and affect the alternative splicing of SMN2 exon-
7. 
 
5.1.3 Potential functions of PRMT5 methylation on TRIP6 
TRIP6 was identified as PRMT5 substrate using ProtoArray® system. 
TRIP6 consists of Crm-1-dependent leucine-rich NES, multiple proline-rich 
PXXP motifs in the N-terminal region and three LIM domains in the C-
terminal region. TRIP6 is primarily localized in the cytosol with a leucine-rich 
NES between amino acid residues 100-107.  Both of proline-rich motifs and 
LIM domains of TRIP6 are known to mediate the protein-protein interactions. 
TRIP6 is an adaptor protein that regulates diverse cellular responses, including 
cell motility, antiapoptotic signaling and transcriptional control (Lin & Lin 
2011). Due to the multiple functions of TRIP6, it is relatively hard to predict 
the putative functions of its arginine modification. Since two RGG/RG motifs 
are localized in the proline-rich regions, it is possible that arginine methylation 
of TRIP6 might involve in modulating the specific protein-protein interactions, 
which can be determined using the immunoprecipitation of wild type or 
arginine mutant TRIP6 in conjunction with mass spectrometry. Understanding 
the possible functions of arginine methylation in regulating protein-protein 
interaction will help in elucidating the downstream responses.  	  
5.1.4 Biochemical studies of the PRDM9 and PRDM15 PR domains 
PRDM9, an important protein for hotspot specification, was first 
identified to only tri-methylate H3K4. Our initial trial showed that the PRDM9 
PR domain exhibited wide substrate specificity on histone proteins when a 
high amount of enzyme was used. At more limited levels, PRDM9 only mono-
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, di- and tri-methylates histone H3 on lysine 4, and mono-methylates histone 
H4 on lysine 20. PRDM9 binds to histone H3 and cofactor SAM with Kds ~ 
17.6 and 42.6 µM, respectively. With the pre-incubation of peptide substrate, 
PRDM9 PR domain shows greater propensity for SAH binding. Using the 
ProtoArray® microarray, UNG and EDC3 were identified as the non-histone 
substrates for the PRDM9 PR domain, and EDC3 was further validated by in 
vitro methylation assay. Although PRDM9 is such an active 
methyltransferase, we did not obtain many hits on our protein arrays, which 
might be due to the antibody specificity or the nature of the PRDM9 PR 
domain. This biochemical characterization of PRDM9 can provide a template 
for studying the enzymatic activity of other PRDM family members.  
In contrast, the catalytic activity and crystal structure of PRDM15 have 
not been reported. The in vitro methylation assay of PRDM15 PR on histones 
and the ProtoArray® microarray suggest this PR domain is catalytic inactive. 
Moreover, the crystal structure of the PRDM15 PR domain alone does not 
seem to allow the binding to cofactor SAM. Thus, PRDM9 and PRDM15 are 
two distinct examples from PRDM family. One is very enzymatically active 
on histones, while the other is totally inactive. Based on the structural 
comparison of these two PR domains, we found that many residues in the 
catalytic domain of PRDM15 are not conserved, which likely results in the 
loss of PRDM9-like interaction with SAM. Although the amino acid sequence 
conservation is important for enzymatic activity, each PRDM protein may also 
depend on other domains or other binding partners to be functional. As the 
most diverged subfamily from SET domain-containing proteins, PR domains 
in PRDM family maybe relatively degenerated in their catalytic activity, and 
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act as transcription factors together with various numbers of zinc fingers and 
other domains.  
 
5.1.5  Potential roles of PRDM9 methylation on EDC3 
EDC3 was identified as PRDM9 substrate by ProtoArray® microarray, 
which still need the in vivo validation in future. EDC3 protein consists of an 
N-terminal divergent Lsm domain, a central FDF domain, a C-terminal Yjef-N 
domain, and a low-complexity linker between the Lsm and FDF domains. 
EDC3 is a component of a multiprotein complex that contains the decapping 
enzyme DCP2 and several decapping activators. The Lsm domain of EDC3 
mediates the DCP1 binding and P-body localization (Tritschler et al. 2007). 
The linker region of EDC3 interacts with DCP2 and the FDF domain with 
Me31B. In addition, both of Lsm and FDF domains are involved in RNA 
binding, which is enhanced by the presence of the YjeF-N domain (Ling et al. 
2008). We suspect the lysine methylation of EDC3 might play a role in 
regulating its interaction with either the decapping complex or RNA, which 
could affect the decapping function and mRNA degradation.  
 
5.1.6 ProtoArray® microarray 
In this study, the ProtoArray® microarray was applied to identify the 
substrates for both protein arginine and lysine methyltransferase via 
florescence-based detection approach. Through the in vitro ProtoArray® 
microarray system, we identified many high confidence hits as PRMT5 
substrates. As the first description of this method to profile PRMT substrates, 
we have illustrated the details of data analysis and the possible non-specific 
	  	  
107	  	  
binding caused by the antibody. These data are dependent on the specificity of 
the antibody and the strength of methylation signals. Prudent data analysis is a 
critical step in determining the most promising targets. First, we filtered the 
data by Z-Factor, Z-Score and spot CV on each array. The hits that passed 
these three statistical parameters from each array were then compared. The Z-
Score reflects how many standard deviations a particular protein signal is 
above the mean signal for all protein features. The default cut-off for Z-Score 
in this system is 3, which is relatively stringent. When fewer hits were 
obtained, the lower Z-Score value can be used for analysis. We were able to 
identify the substrate for PRDM9 using Z-Score >2.  Next, signal ratios were 
calculated from the comparative overlapped region of control and 
experimental arrays. This is particularly important for the sdme-RG antibody, 
which has the non-specific binding to many unmethylated RGG/RG motif-
containing proteins in the control array. Only the proteins with signal ratio 
higher than 1.5 were selected as the putative substrates for the particular 
methyltransferase. With the availability of specific antibodies for PTMs, this 
system can be widely used to profile substrates for other enzymes in future.  
Apart from the above statistical analysis, several other experimental 
factors are also important in determining the results. In our PRMT5 
ProtoArray® dataset, we notice that many hits from PRMT5-1 and PRMT5-2 
are not overlapped, which is because that the PRMT5-1 and PRMT5-2 arrays 
are performed at different time. Hence, it is critical that the control and 
experimental arrays must be performed and scanned at the same time. The 
primary antibody incubation time also determines the number of hits. The 
room temperature incubation for 1h of primary antibody on microarray results 
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in less number of hits in comparison with 4°C incubation for overnight. The 
wash buffer, the methylation buffer, the antibody dilution and the scanner 
settings should be same for both control and experimental arrays. While the 
new enzyme and primary antibody are performed on microarray, it would be 
great to optimize the suitable buffer condition and antibody dilution.   
 
5.1.7  Arginine and lysine methylation 
The cofactor SAM is the common methyl donor for both PRMTs and 
PKMTs in catalyzing methylation. The SAM binding domains of PRMTs and 
PKMTs are different in amino acid sequence and in structural conformation. 
PRMTs-mediated arginine and PKMTs-mediated lysine methylation are two 
common PTMs on histone proteins. Histone arginine and lysine methylation 
can be mutually exclusive. The asymmetric dimethylation of H3R2 by 
PRMT6 has been shown to block the trimethylation of H3K4 by inhibiting the 
binding of MLL/WDR5 to histone H3 tail (Guccione et al. 2007). Conversely, 
the H3K4me3 mark also impairs the asymmetric dimethylation of H3R2. The 
crosstalk between arginine and lysine methylation also occurs between 
H3R8/H3K9 and H3R26/H3K27 (Migliori et al 2010). This crosstalk plays an 
important role in regulating and modulating the chromatin-binding proteins on 
histone tails.   
 
5.2 FUTURE WORK 
5.2.1 Functional effects of arginine methylation on SFPQ 
SFPQ, a multifunctional protein, was known as a substrate of PRMT1 
(Snijders et al. 2015). The asymmetric arginine dimethylation is antagonized 
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by the citrullination. Moreover, arginine methylation of SFPQ was shown to 
increase the association with mRNA (Snijders et al. 2015). There is a serine 
residue between Arg7 and Arg9 of SFPQ. This Ser8 is the phosphorylation 
site of MNK2 kinase (Buxade et al. 2008).  It would be interesting to test 
whether this phosphorylation will affect arginine methylation or citrullination.  
 
5.2.2 Functional effects of symmetric arginine dimethylation of 
KHDRBS1 by PRMT5 
KHDRBS1 (SAM68) is a sequence-specific RNA binding protein that 
is involved in RNA metabolism including alternative splicing and polysomal 
recruitment of RNA (Huot et al. 2012; Paronetto et al. 2009). KHDRBS1 was 
known as a substrate of PRMT1 (Bedford 2003). KHDRBS1 was found to 
localize in the nucleus in normal ES cells, however, KHDRBS1 was partially 
translocated to the cytoplasm in PRMT1 -/- ES cells (Bedford 2003). Since 
KHDRBS1 was identified as a PRMT5 substrate, it would be interesting to 
look at its cellular localization in PRMT5 -/- cells.  KHDRBS1 was also found 
to shuttle between the nucleus and cytoplasm in secondary spermatocytes, 
which causes a substantial portion of KHDRBS1 to associate with polysome 
(Enjalbert et al. 2006). If lack of PRMT5 leads to the shuttling of KHDRBS1, 
it would be intriguing to know whether there is a change of the association of 
KHDRBS1 with the polysome.  
 
5.2.3 Functional effects of arginine methylation of hnRNPs by PRMT5 
Heterogeneous ribonucleoproteins (hnRNPs) play multifunctional roles 
in RNA metabolism, including pre-mRNA splicing, mRNA export, 
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localization, translation, and stability. They mainly localize in nucleus and 
shuttle to cytoplasm for certain functions. Many hnRNPs were known to be 
arginine methylated and also identified in hmSILAC (Liu & Dreyfuss 1995) 
(Ong et al. 2004). PRMT1 can catalyze arginine methylation in many hnRNPs. 
Some studies have shown that arginine methylation affects the interaction 
between some hnRNPs and nucleic acids, such as hnRNPA1 and SAM68. 
Arginine methylation regulates the cellular localization of some hnRNP 
proteins, like hnRNPK. Here, we identify some hnRNPs as PRMT5 targets. It 
would be particularly interesting to investigate the regulation of pre-mRNA 
splicing by arginine methylation on hnRNPs.  
 
5.2.4 Functional studies of arginine methylation of TRIP6 
TRIP6 was identified from PRMT5 substrate profiling on the protein 
microarray system. TRIP6 has not been reported as a substrate of any protein 
methyltransferase. Therefore, immunoprecipitation of endogenous TRIP6 
following by mass spectrometry will help in understanding whether TRIP6 
contains any arginine modifications. Assuming that TRIP6 contains 
symmetrically dimethylated arginines, Western blot analysis against this 
modification can be performed on wild type or PRMT5-/- NPCs to know 
whether there is a reduction in methylation. Next, the functional effects of 





5.2.5 Substrate profiling of PRMT9 and PRMT1 using the ProtoArray® 
microarray 
Type II protein arginine methyltransferase PRMT9 was only known to 
methylate splicing factor 145 (Yang et al. 2015). It would be worth profiling 
the substrates of PRMT9 using the ProtoArray® microarray, which will help 
understand the additional functions of this novel PRMT.  Apart from sdme-RG 
antibody, there is an antibody against asymmetric di-methyl arginine motif 
[adme-R] (#13522, CST). It would be interesting to perform the substrates 
profiling for PRMT1 using this antibody.  
 
5.2.6 Determination of EDC3 methylation by PRDM9 in vivo  
As an enhancer of decapping, EDC3 has not been reported to contain 
methylated lysine residues. It would be interesting to perform the 
immunoprecipitation of endogenous EDC3 from human cells and analyze 
using mass spectrometry for the post-translational modifications. PRDM9 
might not be the only lysine methyltransferase to methylate EDC3. Using 
mass spectrometry, we can also determine whether the immunoprecipitation of 
EDC3 can pull down any methyltransferase. To know whether PRDM9 can 
methylate EDC3 in vivo, we can co-express the wild type or catalytic mutant 
PRDM9 with EDC3 in cells and immunoprecipitate EDC3 for Western blot 
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Table A1. hmSILAC dataset for NPCs.    Heavy WT and light PRMT5 -/- 
samples were analyzed using HCD (1a), CID (1b), and HCD (1c). Heavy 
PRMT5-/- and light WT samples were analyzed by HCD (2a) and CID (2b). 
Intensity log2(heavy/light ratio) was calculated for 1a, 1b, 1c, 2a and 2b. The 
Log2(heavy/light ratio) > 0 is highlighted in red and  Log2(heavy/light ratio) < 





symbol Modified sequence Site 1a 1b 1c 2a 2b 
H7BXB9 
1700037H0
4RIK (ac)AAANR(di)GSK 6 




4RIK (ac)AAANR(me)GSK(me) 6 
    
-3.01 
O08583 ALYREF SQR(di)GGR(di)GGGR(di)GR 23 
   
-1.25 
 
O08583 ALYREF SQR(di)GGR(di)GGGR(di)GR 20 
   
-1.25 
 
O08583 ALYREF SQR(di)GGR(di)GGGR(di)GR 27 
   
-1.25 
 
O08583 ALYREF GGSR(di)GR(di)GR(di)GTGR 226 
   
-1.22 
 
O08583 ALYREF GGSR(di)GR(di)GR(di)GTGR 224 
   
-1.22 
 
O08583 ALYREF GGSR(di)GR(di)GR(di)GTGR 222 
   
-1.22 
 
O08583 ALYREF PAQSINR(di)GGM(me)TR 196 
    
-1.37 
O08583 ALYREF PAQSINR(me)GGM(me)TR(me) 196 
    
-1.37 
O08583 ALYREF PAQSINR(me)GGM(me)TR(me) 201 
    
-1.37 








O08583 ALYREF R(me)PAQSINR(me)GGMTR 196 -1.41 
    
O08583 ALYREF R(me)PAQSINR(me)GGMTR 189 -1.41 
    
O08583 ALYREF NRPAIAR(me)GAAGGGR(me) 63 -1.26 
    
O08583 ALYREF NRPAIAR(me)GAAGGGR(me) 70 -1.26 
    
O08583 ALYREF RPAQSINR(di)GGM(ox)TR 196 
   
1.06 
 
G3UXT8 BAG6 (ac)GGGGR(di)R(di) 27 
 
1.12 
   
G3UXT8 BAG6 (ac)GGGGR(di)R(di) 26 
 
1.12 
   
G3UXT8 BAG6 (ac)GGGGR(di)R 26 
 
-26.92 






   
Q8K019 BCLAF1 SPRR(di)GR(di)SR(di) 111 
 
0.98 
   
Q8K019 BCLAF1 SPRR(di)GR(di)SR(di) 109 
 
0.98 
   
Q8K019 BCLAF1 SPRR(di)GR(di)SR(di) 107 
 
0.98 
   
Q9D1P4 CHORDC1 R(me)PSPDEPM(ox)TNLELK 108 
    
-1.48 
Q04447 CKB DLFDPIIEER(me) 96 
 
-1.14 






   
Q5SXR6 CLTC NNLAGAEELFAR(me) 370 2.87 
    








P53996 CNBP ECPTGGGR(di)GR(di)GM(me)R 25 1.34 
    
P53996 CNBP ECPTGGGR(di)GR(di)GM(me)R 27 1.34 
    













symbol Modified sequence Site 1a 1b 1c 2a 2b 
P53996 CNBP ECPTGGGR(di)GR(di)GMR 25 
   
-2.05 
 
P53996 CNBP ECPTGGGR(di)GR(di)GMR 27 
   
-2.05 
 
P56546 CTBP2 ICEGIR(di)PQIM(me)NGPLHPR 22 
    
-1.05 
P56546 CTBP2 ICEGIR(di)PQIMNGPLHPR 22 
    
-1.05 




Q8VHK9 DHX36 GSGGGGGGR(di)GGR(di)GR 40 
   
-2.91 
 
Q8VHK9 DHX36 GSGGGGGGR(di)GGR(di)GR 43 
   
-2.91 
 
Q8VHK9 DHX36 R(me)GFM(ox)QGHVNRQEK 413 
 
-14.02 















O70133 DHX9 YGDGPR(di)PPK 1161 
  
-1.92 1.28 1.15 
Q5U458 DNAJC11 LM(ox)QESVR(di)R(di) 451 
 
-1.49 
   
Q5U458 DNAJC11 LM(ox)QESVR(di)R(di) 450 
 
-1.49 
   
E9PWE8 DPYSL3 TLDFDALSVGQR(di)GAK 60 
 
2.77 
   
E9PWE8 DPYSL3 TLDFDALSVGQR(me)GAK(me) 60 
 
2.77 
   




P58252 EEF2 M(ox)VPTSDK(me)GR(me) 409 
 
-2.01 














    
-1.21 
Q9WUK












P70459 ERF YYYNK(me)R(me) 92 










Q5SUS9 EWSR1 GSR(di)GNPSGGGNVQHR 511 
 
0.28 
   
Q8CFQ9 FUS GGR(di)GR(di)GGGGGYNR 216 -0.98 
 
-1.08 -1.03 1.23 
Q8CFQ9 FUS GGR(di)GR(di)GGGGGYNR 218 -0.98 
 
-1.08 -1.03 1.23 




P97855 G3BP1 PGFGVGR(di)GITTPR 458 7.94 
    
P97855 G3BP1 PESKPDSQIPPQR(me)PQR 294 
 
-1.27 
   









   
E9Q2E4 GM15800 
PTYSVLLGQLFAFIGTNPDQAVSSSS
FLLAAQTR(di) 1611 -1.75 
    
O88630 GOSR1 (ac)AAGTSNYWEDLR(di)K(di) 13 
    
-1.45 


























   
-2.32 
 
Q5EBP8 HNRNPA1 QEMASASSSQR(me) 194 



















































Q8BG05 HNRNPA3 QEM(ox)QSAGSQR(me) 214 
 
1.77 
   
Q8BG05 HNRNPA3 QEMQSAGSQR(me) 214 
 
2.36 
   
Q8BG05 HNRNPA3 KLFIGGLSFETTDDSLR(me) 52 
    
-2.79 





Q99020 HNRNPAB R(di)GGHQNNYKPY 275 1.16 1.24 1.23 -1.32 -1.52 
Q99020 HNRNPAB GNR(me)GSGGGQGSTNYGK 258 
 
1.15 
   
Q99020 HNRNPAB EVYQQQQYGSGGR(me)GNR(me) 253 -1.61 
    
Q99020 HNRNPAB EVYQQQQYGSGGR(me)GNR(me) 250 -1.61 
    

















    
1.71 
P70333 HNRNPH2 PGAGR(di)GYNSIGR(di)GAGFER 224 2.56 3.40 3.05 -2.47 
 
P70333 HNRNPH2 PGAGR(di)GYNSIGR(di)GAGFER 217 2.56 3.40 3.05 -2.47 
 
P70333 HNRNPH2 (ac)M(ox)LSTEGR(me)EGFVVKVR 8 























J3QNY1 hnRNPK QEMQSAGSQR(me) 192   0.42  -3.29 
P61979 hnRNPK PVGFPMR(di)GR(di)GGFDR 187 0.65   -1.37  
P61979 hnRNPK PVGFPMR(di)GR(di)GGFDR 189 0.65   -1.37  
Q00PI9 
HNRNPUL
2 AYGQQYWGQSGNRGGYR(di) 686 




2 AYGQQYWGQSGNR(di)GGYR 682 -1.20 
    
Q9Z1X4 ILF3 TPVPVR(me)GGPK(me) 609 
 
1.43 
   
Q9Z1X4 ILF3 TPVPVR(di)GGPK 609 -0.97 -1.01 1.01 0.92 
 
Q60749 KHDRBS1 PR(di)GGGGGPR(di)GGAR 52 1.05 -1.25 1.18 
 
-2.06 
Q60749 KHDRBS1 PR(di)GGGGGPR(di)GGAR 45 1.05 -1.25 1.18 
 
-2.06 
Z4YJT3 LARP1 EGRTLDAKM(ox)PR(me)K 793 
    
2.16 
Q3U4X8 LIG1 KGETSAANM(ox)QR(me) 19 
 
1.53 
   
Q8K310 MATR3 
TEEGPTLSYGR(me)DGR(me)SATR(
me) 160 2.24 
    
Q8K310 MATR3 
TEEGPTLSYGR(me)DGR(me)SATR(
me) 167 2.24 
    
Q8K310 MATR3 
TEEGPTLSYGR(me)DGR(me)SATR(
me) 163 2.24 
    
Q9D7W5 MED8 QLTTDAAR(me)IGADAAQK 130 
    
1.36 
Q9CQ20 MID1IP1 HSLFNAM(me)NR(me) 20 








symbol Modified sequence Site 1a 1b 1c 2a 2b 
Q8K2Z4 NCAPD2 LQEM(me)R(me)AQR(me) 464 
    
2.64 
Q8K2Z4 NCAPD2 LQEM(me)R(me)AQR(me) 461 
    
2.64 
Q6P5H2 NES SSETENIESLETVGECLGR(me) 1124 




ATPAVR 493 0.06 1.18 1.27 -1.85 -1.84 
P29341 PABPC1 
VANTSTQTM(ox)GPR(me)PAAAAA
































AATPAVR(me) 506 0.06 -0.01 1.27 -1.85 -1.84 
P29341 PABPC1 
VANTSTQTM(me)GPR(me)PAAAAA
AATPAVR(me) 493 0.06 -0.01 1.27 -1.85 -1.84 







GPGR 17 1.92 1.25 -1.49 
 
-2.34 
D6RH37 PKN1 (ac)M(ox)ACRPCR(me)GAGR(me) 11 
    
1.05 
D6RH37 PKN1 (ac)M(ox)ACRPCR(me)GAGR(me) 7 
    
1.05 
P17742 PPIA EGM(me)NIVEAMER(me) 144 1.42 
    
A2AR02 PPIG SR(me)SR(me)DR(me)FR(me) 352 
 
0.86 
   
A2AR02 PPIG SR(me)SR(me)DR(me)FR(me) 350 
 
0.86 
   
A2AR02 PPIG SR(me)SR(me)DR(me)FR(me) 348 
 
0.86 
   
A2AR02 PPIG SR(me)SR(me)DR(me)FR(me) 346 
 
0.86 
   
B1AZS9 PRDX4 (ac)DHR(di)CR(di)SR 4 
    
-2.77 
B1AZS9 PRDX4 (ac)DHR(di)CR(di)SR 6 
    
-2.77 




E9QQ57 PRX (ac)EAR(me)SRSAEELR 4 
     
Q9R1P0 PSMA4 (ac)SRR(me)YDSR 4 
   
2.07 
 
P34152 PTK2 SFLQVR(di)K(di) 552 







   




Q91VM5 RBMXL1 GPPR(di)GLR(di)GGSGGTR 107 -1.22 
    
Q91VM5 RBMXL1 GPPR(di)GLR(di)GGSGGTR 110 -1.22 
    
Q91VM5 RBMXL1 GLR(di)GGSGGTR 110 1.21 -1.38 -1.31 
  
Q8CHX7 RFTN2 (ac)GCGLR(di)K 6 
    
-5.86 
Q9D1R9 RPL34 (ac)M(ox)VQR(me)LTYR 4 -7.02 
    






















Q3UQA7 SELH (ac)APHGR(me)K(me)R 6 
 
-3.82 
   
Q8VIJ6 SFPQ SR(di)GGGGGGFHR 9 1.42 1.35 1.18 -1.37 
 






symbol Modified sequence Site 1a 1b 1c 2a 2b 
Q8VIJ6 SFPQ R(di)GGGGGR(di)GGLHDFR 25 1.45 -0.97 1.00 -1.43 1.14 































    
2.20 
P27048 SNRPB VPLAGAAGGPGIGR(me) 108 
    
2.08 




P62305 SNRPE (ac)AYR(me)GQGQK 4 
   
4.15 
 





















    
-2.03 




















F6QCI0 TAF15 SGGYGGDR(di)GGYGGK 302 
 
2.11 1.48 -1.59 -2.96 






F6RX08 TPR (ac)ULIQSLR(di)EDLSK(di) 6 
    
-4.74 
P62996 TRA2B SYR(di)GGGGGGGGWR 241 -1.13 -1.18 -1.76 -1.24 1.25 



















Q91W86 VPS11 GLCTDYRPSLEGR(me)GDR 578 
 
-1.28 
   
Q9DBR1 XRN2 RDDHR(di)GGR 926 
 
-1.10 
   
Q91YT7 YTHDF2 (ac)M(ox)SASSLLEQR(di)PK(di) 10 
 
1.25 
   
P68254 YWHAQ AVTEQGAELSNEER(me) 41 -1.69 -3.43 
   
E9Q8K8 ZC3H4 GM(me)GR(di)GR(di) 294 
 
-1.24 
   
E9Q8K8 ZC3H4 GM(me)GR(di)GR(di) 292 
 
-1.24 
    
 
